BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465. [PMID: 22658128 DOI: 10.1056/nejmoa1200694] [Cited by in Crossref: 4792] [Cited by in F6Publishing: 2849] [Article Influence: 479.2] [Reference Citation Analysis]
Number Citing Articles
1 Wang W, Shen G, Wu S, Song S, Ni Y, Suo Z, Meng X, Li D, Zhou L, Hao R, Zhao Y, Bai L, Hou L, Liu B, Liu G. PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. Oncotarget 2017;8:50782-91. [PMID: 28881603 DOI: 10.18632/oncotarget.15006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kwak G, Kim D, Nam GH, Wang SY, Kim IS, Kim SH, Kwon IC, Yeo Y. Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. ACS Nano 2017;11:10135-46. [PMID: 28985469 DOI: 10.1021/acsnano.7b04717] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 9.8] [Reference Citation Analysis]
3 Gerner MY, Heltemes-Harris LM, Fife BT, Mescher MF. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol 2013;191:1011-5. [PMID: 23804712 DOI: 10.4049/jimmunol.1300652] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
4 Feld E, Horn L. Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. Onco Targets Ther 2017;10:3697-708. [PMID: 28769573 DOI: 10.2147/OTT.S97903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
5 Bachireddy P, Hainz U, Rooney M, Pozdnyakova O, Aldridge J, Zhang W, Liao X, Hodi FS, O'Connell K, Haining WN, Goldstein NR, Canning CM, Soiffer RJ, Ritz J, Hacohen N, Alyea EP 3rd, Kim HT, Wu CJ. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 2014;123:1412-21. [PMID: 24357730 DOI: 10.1182/blood-2013-08-523001] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
6 Jacobs J, Smits E, Lardon F, Pauwels P, Deschoolmeester V. Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015;2015:158038. [PMID: 26605342 DOI: 10.1155/2015/158038] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
7 van der Werf N, Redpath SA, Azuma M, Yagita H, Taylor MD. Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. PLoS Pathog 2013;9:e1003215. [PMID: 23516361 DOI: 10.1371/journal.ppat.1003215] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
8 Zalba S, Belsúe V, Topp B, de Alwis D, Alvarez M, Trocóniz IF, Berraondo P, Garrido MJ. Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1. Br J Cancer 2021;124:1275-85. [PMID: 33531689 DOI: 10.1038/s41416-020-01239-z] [Reference Citation Analysis]
9 Kersten K, Salvagno C, de Visser KE. Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Front Immunol 2015;6:516. [PMID: 26500653 DOI: 10.3389/fimmu.2015.00516] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
10 Kunert A, Straetemans T, Govers C, Lamers C, Mathijssen R, Sleijfer S, Debets R. TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol 2013;4:363. [PMID: 24265631 DOI: 10.3389/fimmu.2013.00363] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
11 Gil-de-Gómez L, Balgoma D, Montero O. Lipidomic-Based Advances in Diagnosis and Modulation of Immune Response to Cancer. Metabolites 2020;10:E332. [PMID: 32824009 DOI: 10.3390/metabo10080332] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 2018; 24(34): 3834-3848 [PMID: 30228778 DOI: 10.3748/wjg.v24.i34.3834] [Cited by in CrossRef: 163] [Cited by in F6Publishing: 148] [Article Influence: 40.8] [Reference Citation Analysis]
13 Sternschein R, Moll M, Ng J, D'Ambrosio C. Immune Checkpoint Inhibitor-related Pneumonitis. Incidence, Risk Factors, and Clinical and Radiographic Features. Am J Respir Crit Care Med 2018;198:951-3. [PMID: 30095979 DOI: 10.1164/rccm.201803-0525RR] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
14 Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pio R. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012;189:4674-83. [PMID: 23028051 DOI: 10.4049/jimmunol.1201654] [Cited by in Crossref: 162] [Cited by in F6Publishing: 148] [Article Influence: 16.2] [Reference Citation Analysis]
15 Allen CT, Clavijo PE, Van Waes C, Chen Z. Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) 2015;7:2397-414. [PMID: 26690220 DOI: 10.3390/cancers7040900] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
16 Gohil SH, Paredes-Moscosso SR, Harrasser M, Vezzalini M, Scarpa A, Morris E, Davidoff AM, Sorio C, Nathwani AC, Della Peruta M. An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors. Oncoimmunology 2017;6:e1326437. [PMID: 28811962 DOI: 10.1080/2162402X.2017.1326437] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 4.4] [Reference Citation Analysis]
17 Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, Brown L, Lewis A, Davies G, Morrow M, Wilkinson RW. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget 2016;7:18508-20. [PMID: 26918344 DOI: 10.18632/oncotarget.7610] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 10.2] [Reference Citation Analysis]
18 Márquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, González-Cao M, Martín-Algarra S. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med 2015;3:267. [PMID: 26605313 DOI: 10.3978/j.issn.2305-5839.2015.10.27] [Cited by in F6Publishing: 35] [Reference Citation Analysis]
19 Zhao Y, Lee CK, Lin CH, Gassen RB, Xu X, Huang Z, Xiao C, Bonorino C, Lu LF, Bui JD, Hui E. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity 2019;51:1059-1073.e9. [PMID: 31757674 DOI: 10.1016/j.immuni.2019.11.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 23.7] [Reference Citation Analysis]
20 Leitner J, Rieger A, Pickl WF, Zlabinger G, Grabmeier-Pfistershammer K, Steinberger P. TIM-3 does not act as a receptor for galectin-9. PLoS Pathog. 2013;9:e1003253. [PMID: 23555261 DOI: 10.1371/journal.ppat.1003253] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 6.9] [Reference Citation Analysis]
21 Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M, Ghebeh H. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer 2015;14:149. [PMID: 26245467 DOI: 10.1186/s12943-015-0421-2] [Cited by in Crossref: 124] [Cited by in F6Publishing: 117] [Article Influence: 17.7] [Reference Citation Analysis]
22 Chang J, Tran J, Kamel D, Basu A. Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer. BMJ Case Rep 2019;12:e228135. [PMID: 30850565 DOI: 10.1136/bcr-2018-228135] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
23 Hu ZY, Huang WY, Zhang L, Huang B, Chen SC, Li XL. Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis. Ann Transl Med 2020;8:1172. [PMID: 33241021 DOI: 10.21037/atm-20-5865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Lin AY, Lin E. Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors? J Hematol Oncol 2015;8:124. [PMID: 26542241 DOI: 10.1186/s13045-015-0222-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
25 Park D, Shakya R, Koivisto C, Pitarresi JR, Szabolcs M, Kladney R, Hadjis A, Mace TA, Ludwig T. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains. PLoS One 2019;14:e0226714. [PMID: 31877165 DOI: 10.1371/journal.pone.0226714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
26 Zavala VA, Kalergis AM. New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015;145:182-201. [PMID: 25826229 DOI: 10.1111/imm.12459] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
27 Santabarbara G, Maione P, Rossi A, Palazzolo G, Gridelli C. The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. Ann Transl Med 2016;4:215. [PMID: 27386489 DOI: 10.21037/atm.2016.05.64] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
28 Koya T, Yanagisawa R, Higuchi Y, Sano K, Shimodaira S. Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity. Sci Rep 2017;7:42145. [PMID: 28191816 DOI: 10.1038/srep42145] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Rapoport BL, Shannon VR, Cooksley T, Johnson DB, Anderson L, Blidner AG, Tintinger GR, Anderson R. Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. Front Pharmacol 2021;12:743582. [PMID: 34675810 DOI: 10.3389/fphar.2021.743582] [Reference Citation Analysis]
30 Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: Looking to the future. Oncoimmunology 2013;2:e23403. [PMID: 23802081 DOI: 10.4161/onci.23403] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
31 Yoo B, Jordan VC, Sheedy P, Billig AM, Ross A, Pantazopoulos P, Medarova Z. RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy. Sci Rep 2019;9:4712. [PMID: 30886310 DOI: 10.1038/s41598-019-41251-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
32 Roh J, Jeon Y, Lee AN, Lee SM, Kim Y, Sung CO, Park CJ, Hong JY, Yoon DH, Suh C, Huh J, Choi I, Park CS. The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget 2017;8:58122-32. [PMID: 28938542 DOI: 10.18632/oncotarget.19468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
33 Takahashi D, Kojima M, Suzuki T, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Ikeda M, Nakatsura T, Ochiai A, Nagino M. Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification. Sci Rep 2018;8:13166. [PMID: 30177687 DOI: 10.1038/s41598-018-31383-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
34 Curran E, Corrales L, Kline J. Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front Oncol 2015;5:83. [PMID: 25914882 DOI: 10.3389/fonc.2015.00083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
35 Homet Moreno B, Mok S, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunology. 2016;5:e1052212. [PMID: 27622011 DOI: 10.1080/2162402x.2015.1052212] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 7.7] [Reference Citation Analysis]
36 Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, Guo J, Peng H, Chen M, Fu YX, Tang H. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun 2020;11:4835. [PMID: 32973173 DOI: 10.1038/s41467-020-18570-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 21.5] [Reference Citation Analysis]
37 Kleponis J, Skelton R, Zheng L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med 2015;12:201-8. [PMID: 26487965 DOI: 10.7497/j.issn.2095-3941.2015.0046] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
38 Zhou ZX, Zhang HX, Zheng QC. Predicting a Kind of Unusual Multiple-States Dimerization-Modes Transformation in Protein PD-L1 System by Computational Investigation and a Generalized Rate Theory. Front Chem 2021;9:783444. [PMID: 34858950 DOI: 10.3389/fchem.2021.783444] [Reference Citation Analysis]
39 Gelsomino F, Vitale G, Ardizzoni A. A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Invest New Drugs. 2018;36:144-146. [PMID: 28631096 DOI: 10.1007/s10637-017-0484-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
40 Bockamp E, Rosigkeit S, Siegl D, Schuppan D. Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology. Cells 2020;9:E2102. [PMID: 32942725 DOI: 10.3390/cells9092102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Karashima T, Udaka K, Niimura M, Suzuki K, Osakabe H, Shimamoto T, Fukata S, Inoue K, Kuroda N, Seiki M, Shuin T. Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model. Oncol Lett 2017;14:1162-6. [PMID: 28693290 DOI: 10.3892/ol.2017.6235] [Reference Citation Analysis]
42 Xu Y, Cui G, Jiang Z, Li N, Zhang X. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. Oncol Lett 2019;17:2960-8. [PMID: 30854074 DOI: 10.3892/ol.2019.9910] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
43 Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015;106:945-950. [PMID: 25981182 DOI: 10.1111/cas.12695] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
44 Zhang D, Huang J, Zhang C, Guan Y, Guo Q. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer]. Zhongguo Fei Ai Za Zhi 2019;22:369-79. [PMID: 31196371 DOI: 10.3779/j.issn.1009-3419.2019.06.07] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
45 Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut. 2015;64:842-848. [PMID: 25666193 DOI: 10.1136/gutjnl-2014-307990] [Cited by in Crossref: 97] [Cited by in F6Publishing: 105] [Article Influence: 13.9] [Reference Citation Analysis]
46 Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125:3401-3412. [PMID: 26214521 DOI: 10.1172/jci80009] [Cited by in Crossref: 318] [Cited by in F6Publishing: 177] [Article Influence: 45.4] [Reference Citation Analysis]
47 Griffin LL, Cove-Smith L, Alachkar H, Radford JA, Brooke R, Linton KM. Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. JAAD Case Rep 2018;4:229-31. [PMID: 29687056 DOI: 10.1016/j.jdcr.2017.09.028] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
48 Du W, Yang M, Turner A, Xu C, Ferris RL, Huang J, Kane LP, Lu B. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. Int J Mol Sci 2017;18:E645. [PMID: 28300768 DOI: 10.3390/ijms18030645] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 18.6] [Reference Citation Analysis]
49 Hölzel M, Bovier A, Tüting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer. 2013;13:365-376. [PMID: 23535846 DOI: 10.1038/nrc3498] [Cited by in Crossref: 166] [Cited by in F6Publishing: 142] [Article Influence: 18.4] [Reference Citation Analysis]
50 Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, Nawrocki ST, Nuovo G, Mita MM. A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E160. [PMID: 29799479 DOI: 10.3390/cancers10060160] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 12.5] [Reference Citation Analysis]
51 Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014;33:641-55. [PMID: 24477411 DOI: 10.1007/s10555-013-9479-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
52 Chehval V, Norian LA. Effects of obesity on immune responses to renal tumors. Immunol Res 2014;59:211-9. [PMID: 24838144 DOI: 10.1007/s12026-014-8533-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, Kiniwa Y, Okuyama R, Tanaka R, Fujisawa Y, Kato H, Morita A, Asai J, Katoh N, Yokota K, Akiyama M, Ihn H, Fukushima S, Nakamura Y. Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology 2016;5:e1204507. [PMID: 27757299 DOI: 10.1080/2162402X.2016.1204507] [Cited by in Crossref: 74] [Cited by in F6Publishing: 46] [Article Influence: 12.3] [Reference Citation Analysis]
54 Shindo Y, McDonough JS, Chang KC, Ramachandra M, Sasikumar PG, Hotchkiss RS. Anti-PD-L1 peptide improves survival in sepsis. J Surg Res 2017;208:33-9. [PMID: 27993215 DOI: 10.1016/j.jss.2016.08.099] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
55 Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget 2015;6:40836-49. [PMID: 26517811 DOI: 10.18632/oncotarget.5696] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 12.0] [Reference Citation Analysis]
56 Concha-Benavente F, Ferris RL. Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Curr Opin Immunol 2017;45:52-9. [PMID: 28208102 DOI: 10.1016/j.coi.2017.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
57 Kim JY, Lee E, Park K, Park WY, Jung HH, Ahn JS, Im YH, Park YH. Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response. Oncotarget 2017;8:47400-11. [PMID: 28537889 DOI: 10.18632/oncotarget.17653] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
58 Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14:1212-1218. [PMID: 24240160 DOI: 10.1038/ni.2762] [Cited by in Crossref: 532] [Cited by in F6Publishing: 487] [Article Influence: 66.5] [Reference Citation Analysis]
59 Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016;22:470-478. [PMID: 26373575 DOI: 10.1158/1078-0432.ccr-15-0715] [Cited by in Crossref: 102] [Cited by in F6Publishing: 65] [Article Influence: 14.6] [Reference Citation Analysis]
60 LaRocca CJ, Warner SG. A New Role for Vitamin D: The Enhancement of Oncolytic Viral Therapy in Pancreatic Cancer. Biomedicines 2018;6:E104. [PMID: 30400571 DOI: 10.3390/biomedicines6040104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
61 Nishino M, Giobbie-Hurder A, Ramaiya NH, Hodi FS. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer 2014;2:40. [PMID: 25411640 DOI: 10.1186/s40425-014-0040-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
62 Nguyen T, Urban J, Kalinski P. Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther 2014;3:135-50. [PMID: 27471705 DOI: 10.2147/ITT.S40264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
63 Shames DS, Wistuba II. The evolving genomic classification of lung cancer. J Pathol 2014;232:121-33. [PMID: 24114583 DOI: 10.1002/path.4275] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 8.3] [Reference Citation Analysis]
64 Cui S, Su X, Dong L, Qian J, Ye L, Zhang T, Fu H, Han H, Huang J, Yao Y, Gu Y, Jiang L. Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. J Cancer 2017;8:4075-82. [PMID: 29187883 DOI: 10.7150/jca.21415] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
65 Ramesh A, Natarajan SK, Nandi D, Kulkarni A. Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor. Cell Mol Bioeng 2019;12:357-73. [PMID: 31719920 DOI: 10.1007/s12195-019-00576-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
66 Nishimori A, Konnai S, Okagawa T, Maekawa N, Ikebuchi R, Goto S, Sajiki Y, Suzuki Y, Kohara J, Ogasawara S, Kato Y, Murata S, Ohashi K. In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection. PLoS One 2017;12:e0174916. [PMID: 28445479 DOI: 10.1371/journal.pone.0174916] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
67 van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 2015;14:499-509. [PMID: 26129802 DOI: 10.1038/nrd4597] [Cited by in Crossref: 246] [Cited by in F6Publishing: 237] [Article Influence: 35.1] [Reference Citation Analysis]
68 Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, Callahan MK, Atkins MB, Sharon E, Antonia SJ, West P, Gravell AE; Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force collaboration. The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. JNCI Cancer Spectr 2018;2:pky021. [PMID: 30057972 DOI: 10.1093/jncics/pky021] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 14.3] [Reference Citation Analysis]
69 Baylin SB, Jones PA. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 2016;8:a019505. [PMID: 27194046 DOI: 10.1101/cshperspect.a019505] [Cited by in Crossref: 371] [Cited by in F6Publishing: 318] [Article Influence: 61.8] [Reference Citation Analysis]
70 Asimgil H, Ertetik U, Çevik NC, Ekizce M, Doğruöz A, Gökalp M, Arık-Sever E, Istvanffy R, Friess H, Ceyhan GO, Demir IE. Targeting the undruggable oncogenic KRAS: the dawn of hope. JCI Insight 2022;7:e153688. [PMID: 35014625 DOI: 10.1172/jci.insight.153688] [Reference Citation Analysis]
71 Li J, Zhao M, Sun M, Wu S, Zhang H, Dai Y, Wang D. Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment. ACS Appl Mater Interfaces 2020;12:50734-47. [PMID: 33124808 DOI: 10.1021/acsami.0c14909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
72 He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep 2015;5:13110. [PMID: 26279307 DOI: 10.1038/srep13110] [Cited by in Crossref: 198] [Cited by in F6Publishing: 204] [Article Influence: 28.3] [Reference Citation Analysis]
73 Yue X, Chen Q, He J. Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. Cancer Cell Int 2020;20:524. [PMID: 33292251 DOI: 10.1186/s12935-020-01614-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Kleeman SO, Leedham SJ. Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer. Cancers (Basel) 2020;12:E3355. [PMID: 33202731 DOI: 10.3390/cancers12113355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
75 Manzo T, Prentice BM, Anderson KG, Raman A, Schalck A, Codreanu GS, Nava Lauson CB, Tiberti S, Raimondi A, Jones MA, Reyzer M, Bates BM, Spraggins JM, Patterson NH, McLean JA, Rai K, Tacchetti C, Tucci S, Wargo JA, Rodighiero S, Clise-Dwyer K, Sherrod SD, Kim M, Navin NE, Caprioli RM, Greenberg PD, Draetta G, Nezi L. Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. J Exp Med 2020;217:e20191920. [PMID: 32491160 DOI: 10.1084/jem.20191920] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
76 Missiaen R, Mazzone M, Bergers G. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Semin Cancer Biol 2018;52:107-16. [PMID: 29935312 DOI: 10.1016/j.semcancer.2018.06.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
77 Xia AL, Xu Y, Lu XJ. Functional genomics in the era of cancer immunotherapy: challenges and clinical implications. Brief Funct Genomics 2019;18:83-5. [PMID: 30901384 DOI: 10.1093/bfgp/elz003] [Reference Citation Analysis]
78 Bose CK. Immune Checkpoint Blockers and Ovarian Cancer. Indian J Med Paediatr Oncol 2017;38:182-9. [PMID: 28900328 DOI: 10.4103/ijmpo.ijmpo_73_16] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
79 Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res 2013;1:85-91. [PMID: 24777499 DOI: 10.1158/2326-6066.CIR-13-0078] [Cited by in Crossref: 112] [Cited by in F6Publishing: 66] [Article Influence: 12.4] [Reference Citation Analysis]
80 Rajani KR, Vile RG. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses 2015;7:5889-901. [PMID: 26580645 DOI: 10.3390/v7112914] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
81 Kato K, Mizuno T, Koseki T, Ito Y, Hatano M, Takahashi K, Yamada S, Tsuboi N. Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency. In Vivo 2021;35:2831-40. [PMID: 34410975 DOI: 10.21873/invivo.12570] [Reference Citation Analysis]
82 Hepgur M, Sadeghi S, Dorff TB, Quinn DI. Tivozanib in the treatment of renal cell carcinoma. Biologics 2013;7:139-48. [PMID: 23788831 DOI: 10.2147/BTT.S32958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
83 Patel JN, Ersek JL, Kim ES. Lung cancer biomarkers, targeted therapies and clinical assays. Transl Lung Cancer Res 2015;4:503-14. [PMID: 26629419 DOI: 10.3978/j.issn.2218-6751.2015.06.02] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
84 Zhang J, Wolfgang CL, Zheng L. Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel). 2018;10. [PMID: 29385739 DOI: 10.3390/cancers10020039] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
85 You W, Shang B, Sun J, Liu X, Su L, Jiang S. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncol Rep 2020;44:424-37. [PMID: 32627031 DOI: 10.3892/or.2020.7643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
86 Fang WF, Chen YM, Lin CY, Huang KT, Kao HC, Fang YT, Huang CH, Chang YT, Wang YH, Wang CC, Lin MC. Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units. PLoS One 2017;12:e0179749. [PMID: 28692671 DOI: 10.1371/journal.pone.0179749] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
87 Gurbatri CR, Lia I, Vincent R, Coker C, Castro S, Treuting PM, Hinchliffe TE, Arpaia N, Danino T. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med 2020;12:eaax0876. [PMID: 32051224 DOI: 10.1126/scitranslmed.aax0876] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 66.0] [Reference Citation Analysis]
88 Baues C, Semrau R, Gaipl US, Bröckelmann PJ, Rosenbrock J, Engert A, Marnitz S. Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group. Strahlenther Onkol 2017;193:95-9. [PMID: 27704149 DOI: 10.1007/s00066-016-1050-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
89 Xu X, Xie K, Li B, Xu L, Huang L, Feng Y, Pi C, Zhang J, Huang T, Jiang M, Gu H, Fang J. Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression. Int Immunopharmacol 2021;101:108199. [PMID: 34673297 DOI: 10.1016/j.intimp.2021.108199] [Reference Citation Analysis]
90 Karami Fath M, Azargoonjahromi A, Jafari N, Mehdi M, Alavi F, Daraei M, Mohammadkhani N, Mueller AL, Brockmueller A, Shakibaei M, Payandeh Z. Exosome application in tumorigenesis: diagnosis and treatment of melanoma. Med Oncol 2022;39:19. [PMID: 34982284 DOI: 10.1007/s12032-021-01621-8] [Reference Citation Analysis]
91 Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci 2019;20:E4543. [PMID: 31540286 DOI: 10.3390/ijms20184543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
92 Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract 2016;3:11. [PMID: 27904752 DOI: 10.1186/s40661-016-0033-6] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 14.8] [Reference Citation Analysis]
93 Karin N, Wildbaum G. The Role of Chemokines in Shaping the Balance Between CD4(+) T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer Diseases. Front Immunol 2015;6:609. [PMID: 26648938 DOI: 10.3389/fimmu.2015.00609] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
94 Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis 2013;5 Suppl 5:S579-92. [PMID: 24163750 DOI: 10.3978/j.issn.2072-1439.2013.08.52] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
95 Idorn M, Skadborg SK, Kellermann L, Halldórsdóttir HR, Holmen Olofsson G, Met Ö, Thor Straten P. Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model. Oncoimmunology 2018;7:e1450715. [PMID: 30221044 DOI: 10.1080/2162402X.2018.1450715] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
96 Park IH, Yang HN, Lee KJ, Kim TS, Lee ES, Jung SY, Kwon Y, Kong SY. Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer. Oncotarget 2017;8:32722-30. [PMID: 28415798 DOI: 10.18632/oncotarget.16281] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
97 Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015;38:e55-7. [PMID: 25805871 DOI: 10.2337/dc14-2349] [Cited by in F6Publishing: 113] [Reference Citation Analysis]
98 Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-571. [PMID: 25428505 DOI: 10.1038/nature13954] [Cited by in Crossref: 3422] [Cited by in F6Publishing: 3190] [Article Influence: 488.9] [Reference Citation Analysis]
99 Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 2020;17:807-21. [PMID: 32612154 DOI: 10.1038/s41423-020-0488-6] [Cited by in Crossref: 66] [Cited by in F6Publishing: 76] [Article Influence: 33.0] [Reference Citation Analysis]
100 Oh T, Ivan ME, Sun MZ, Safaee M, Fakurnejad S, Clark AJ, Sayegh ET, Bloch O, Parsa AT. PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. Immunotherapy 2014;6:737-53. [PMID: 25186604 DOI: 10.2217/imt.14.35] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
101 Lau SP, van Montfoort N, Kinderman P, Lukkes M, Klaase L, van Nimwegen M, van Gulijk M, Dumas J, Mustafa DAM, Lievense SLA, Groeneveldt C, Stadhouders R, Li Y, Stubbs A, Marijt KA, Vroman H, van der Burg SH, Aerts J, van Hall T, Dammeijer F, van Eijck CHJ. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. J Immunother Cancer 2020;8:e000772. [PMID: 32690771 DOI: 10.1136/jitc-2020-000772] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
102 Lin S, Huang G, Cheng L, Li Z, Xiao Y, Deng Q, Jiang Y, Li B, Lin S, Wang S, Wu Q, Yao H, Cao S, Li Y, Liu P, Wei W, Pei D, Yao Y, Wen Z, Zhang X, Wu Y, Zhang Z, Cui S, Sun X, Qian X, Li P. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs 2018;10:1301-11. [PMID: 30204048 DOI: 10.1080/19420862.2018.1518948] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
103 Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 2014;9:1036-40. [PMID: 24926549 DOI: 10.1097/JTO.0000000000000177] [Cited by in Crossref: 150] [Cited by in F6Publishing: 70] [Article Influence: 21.4] [Reference Citation Analysis]
104 Osoegawa A, Hiraishi H, Hashimoto T, Takumi Y, Abe M, Takeuchi H, Miyawaki M, Okamoto T, Sugio K. The Positive Relationship Between γH2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. In Vivo 2018;32:171-7. [PMID: 29275316 DOI: 10.21873/invivo.11221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
105 Zheng H, Siddharth S, Parida S, Wu X, Sharma D. Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation. Cancers (Basel) 2021;13:3357. [PMID: 34283088 DOI: 10.3390/cancers13133357] [Reference Citation Analysis]
106 Lv D, Xing C, Cao L, Zhuo Y, Wu T, Gao N. PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer. Oncol Lett 2020;19:1223-34. [PMID: 31966052 DOI: 10.3892/ol.2019.11221] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
107 Yugawa K, Itoh S, Iseda N, Kurihara T, Kitamura Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Yoshizumi T, Mori M. Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status. Sci Rep 2021;11:5845. [PMID: 33712681 DOI: 10.1038/s41598-021-85186-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
108 Ingold Heppner B, Loibl S, Denkert C. Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. Breast Care (Basel) 2016;11:96-100. [PMID: 27239170 DOI: 10.1159/000444357] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
109 Han Z, Liu S, Lin H, Trivett AL, Hannifin S, Yang, Oppenheim JJ. Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses. Cancer Immunol Immunother 2019;68:1073-85. [PMID: 31161238 DOI: 10.1007/s00262-019-02338-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
110 Tesone AJ, Svoronos N, Allegrezza MJ, Conejo-Garcia JR. Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer. Front Immunol 2013;4:435. [PMID: 24339824 DOI: 10.3389/fimmu.2013.00435] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
111 Katsuta E, DeMasi SC, Terracina KP, Spiegel S, Phan GQ, Bear HD, Takabe K. Modified breast cancer model for preclinical immunotherapy studies. J Surg Res 2016;204:467-74. [PMID: 27565084 DOI: 10.1016/j.jss.2016.06.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
112 Kirk R. From ASCO-immunotherapy: programming cancer cell death. Nat Rev Clin Oncol 2012;9:427. [PMID: 22710340 DOI: 10.1038/nrclinonc.2012.104] [Reference Citation Analysis]
113 Del Re M, Vivaldi C, Rofi E, Salani F, Crucitta S, Catanese S, Fontanelli L, Massa V, Cucchiara F, Fornaro L, Capuano A, Fogli S, Vasile E, Danesi R. Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. Cancers (Basel) 2021;13:3738. [PMID: 34359638 DOI: 10.3390/cancers13153738] [Reference Citation Analysis]
114 Long L, Zhang X, Chen F, Pan Q, Phiphatwatchara P, Zeng Y, Chen H. The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9:176-189. [PMID: 30603054 DOI: 10.18632/genesandcancer.180] [Cited by in Crossref: 129] [Cited by in F6Publishing: 119] [Article Influence: 32.3] [Reference Citation Analysis]
115 Kruger S, Legenstein ML, Rösgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, Boeck S. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology 2017;6:e1310358. [PMID: 28638732 DOI: 10.1080/2162402X.2017.1310358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
116 Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer 2015;3:36. [PMID: 26288737 DOI: 10.1186/s40425-015-0078-9] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 15.9] [Reference Citation Analysis]
117 Takahashi H, Kawaguchi T, Yan L, Peng X, Qi Q, Morris LGT, Chan TA, Tsung A, Otsuji E, Takabe K. Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1221. [PMID: 32414098 DOI: 10.3390/cancers12051221] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
118 Huang MH, Zhang XB, Wang HL, Li LX, Zeng YM, Wang M, Zeng HQ. Intermittent hypoxia enhances the tumor programmed death ligand 1 expression in a mouse model of sleep apnea. Ann Transl Med 2019;7:97. [PMID: 31019947 DOI: 10.21037/atm.2019.01.44] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
119 Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11:509-524. [PMID: 25001465 DOI: 10.1038/nrclinonc.2014.111] [Cited by in Crossref: 454] [Cited by in F6Publishing: 426] [Article Influence: 56.8] [Reference Citation Analysis]
120 Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH. New treatment options for metastatic renal cell carcinoma. ESMO Open 2017;2:e000185. [PMID: 28761748 DOI: 10.1136/esmoopen-2017-000185] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
121 Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother 2016;12:2777-89. [PMID: 27398650 DOI: 10.1080/21645515.2016.1199310] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
122 Castellanos EH, Feld E, Estrada MV, Sanders ME, Massion PP, Johnson DB, Balko JM, Horn L. Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy. JCO Precis Oncol 2017;1:PO. [PMID: 32913978 DOI: 10.1200/PO.17.00049] [Reference Citation Analysis]
123 Al-Mansour Z, Pang L, Bathini V. Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient? Drugs Aging 2019;36:1-11. [PMID: 30478744 DOI: 10.1007/s40266-018-0619-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
124 Zeng W, Qin S, Wang R, Zhang Y, Ma X, Tian F, Liu XR, Qin X, Liao S, Sun L, Lin Y. PDL1 blockage increases fetal resorption and Tfr cells but does not affect Tfh/Tfr ratio and B-cell maturation during allogeneic pregnancy. Cell Death Dis 2020;11:119. [PMID: 32051396 DOI: 10.1038/s41419-020-2313-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
125 Zhang J, Wang YF, Wu B, Zhong ZX, Wang KX, Yang LQ, Wang YQ, Li YQ, Gao J, Li ZS. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma. Curr Mol Med 2017;17:689-98. [PMID: 29521231 DOI: 10.2174/1566524018666180308115705] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
126 Namikawa T, Ishida N, Tsuda S, Fujisawa K, Munekage E, Iwabu J, Munekage M, Uemura S, Tsujii S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab. Surg Case Rep 2018;4:71. [PMID: 29978335 DOI: 10.1186/s40792-018-0479-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
127 Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 2016;7:59976-86. [PMID: 27527850 DOI: 10.18632/oncotarget.11045] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
128 Im JS, Herrmann AC, Bernatchez C, Haymaker C, Molldrem JJ, Hong WK, Perez-Soler R. Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. PLoS One 2016;11:e0160004. [PMID: 27467256 DOI: 10.1371/journal.pone.0160004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
129 Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, Kluger HM, Jilaveanu LB. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015;6:24990-5002. [PMID: 26317902 DOI: 10.18632/oncotarget.4572] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
130 Gu Z, Da Silva CG, Van der Maaden K, Ossendorp F, Cruz LJ. Liposome-Based Drug Delivery Systems in Cancer Immunotherapy. Pharmaceutics 2020;12:E1054. [PMID: 33158166 DOI: 10.3390/pharmaceutics12111054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
131 Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24:743-750. [PMID: 24782321 DOI: 10.1101/gr.165985.113] [Cited by in Crossref: 399] [Cited by in F6Publishing: 372] [Article Influence: 49.9] [Reference Citation Analysis]
132 Martinez-Morilla S, McGuire J, Gaule P, Moore L, Acs B, Cougot D, Gown AM, Yaziji H, Wang WL, Cartun RW, Hornick JL, Sholl LM, Qiu J, Mino-Kenudson M, Yi ES, Beasley MB, Merrick DT, Ambaye AB, Zhang ZJ, Walker J, Rimm DL. Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. Lab Invest 2020;100:4-15. [PMID: 31409885 DOI: 10.1038/s41374-019-0295-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
133 Huang X, Zhang X, Xu J, Wang X, Zhang G, Tang T, Shen X, Liang T, Bai X. Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity. Front Oncol 2020;10:1289. [PMID: 32850399 DOI: 10.3389/fonc.2020.01289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
134 Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19:3936-3943. [PMID: 23743568 DOI: 10.1158/1078-0432.ccr-13-0895] [Cited by in Crossref: 291] [Cited by in F6Publishing: 142] [Article Influence: 32.3] [Reference Citation Analysis]
135 Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, Sharpe AH, Dustin LB, Rice CM, Grakoui A, Ahmed R, Walker CM. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci USA. 2013;110:15001-15006. [PMID: 23980172 DOI: 10.1073/pnas.1312772110] [Cited by in Crossref: 133] [Cited by in F6Publishing: 126] [Article Influence: 14.8] [Reference Citation Analysis]
136 Simovic B, Walsh SR, Wan Y. Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy. Oncolytic Virother 2015;4:157-67. [PMID: 27512679 DOI: 10.2147/OV.S66079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
137 Skrombolas D, Sullivan M, Frelinger JG. Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9. J Interferon Cytokine Res 2019;39:233-45. [PMID: 30848689 DOI: 10.1089/jir.2018.0129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Xie F, Zhang J, Wang J, Reuben A, Xu W, Yi X, Varn FS, Ye Y, Cheng J, Yu M, Wang Y, Liu Y, Xie M, Du P, Ma K, Ma X, Zhou P, Yang S, Chen Y, Wang G, Xia X, Liao Z, Heymach JV, Wistuba II, Futreal PA, Ye K, Cheng C, Xia T. Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. Clin Cancer Res 2020;26:2908-20. [PMID: 31911545 DOI: 10.1158/1078-0432.CCR-19-1744] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
139 Georgantzoglou N, Kokkali S, Tsourouflis G, Theocharis S. Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success? Cancers (Basel) 2021;13:1798. [PMID: 33918733 DOI: 10.3390/cancers13081798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
140 Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, Patrizio A, Vita R, Benvenga S, Materazzi G, Fallahi P, Antonelli A. Novel treatments for anaplastic thyroid carcinoma. Gland Surg 2020;9:S28-42. [PMID: 32055496 DOI: 10.21037/gs.2019.10.18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
141 Kim JE, Lim M. The role of checkpoints in the treatment of GBM. J Neurooncol 2015;123:413-23. [PMID: 25749875 DOI: 10.1007/s11060-015-1747-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
142 Deng R, Cassady K, Li X, Yao S, Zhang M, Racine J, Lin J, Chen L, Zeng D. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease. J Immunol 2015;194:560-74. [PMID: 25488990 DOI: 10.4049/jimmunol.1402157] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
143 Mimura N, Hideshima T, Anderson KC. Novel therapeutic strategies for multiple myeloma. Exp Hematol 2015;43:732-41. [PMID: 26118499 DOI: 10.1016/j.exphem.2015.04.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 8.9] [Reference Citation Analysis]
144 Pezzuto F, Fortarezza F, Lunardi F, Calabrese F. Are there any theranostic biomarkers in small cell lung carcinoma? J Thorac Dis 2019;11:S102-12. [PMID: 30775033 DOI: 10.21037/jtd.2018.12.14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
145 Xiao Y, Lai Y, Yu Y, Jiang P, Li Y, Wang C, Zhang R. The Exocrine Differentiation and Proliferation Factor (EXDPF) Gene Promotes Ovarian Cancer Tumorigenesis by Up-Regulating DNA Replication Pathway. Front Oncol 2021;11:669603. [PMID: 34041032 DOI: 10.3389/fonc.2021.669603] [Reference Citation Analysis]
146 Tsao CK, Liaw B, He C, Galsky MD, Sfakianos J, Oh WK. Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2017;9:287-98. [PMID: 28491148 DOI: 10.1177/1758834016687261] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
147 Xiang Z, Zhou Z, Song S, Li J, Ji J, Yan R, Wang J, Cai W, Hu W, Zang L, Zhu Z, Zhang Z, Li M, Yu Y. Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways. Oncogene 2021;40:5002-12. [PMID: 34175886 DOI: 10.1038/s41388-021-01897-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
148 Blair AB, Kim VM, Muth ST, Saung MT, Lokker N, Blouw B, Armstrong TD, Jaffee EM, Tsujikawa T, Coussens LM, He J, Burkhart RA, Wolfgang CL, Zheng L. Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. Clin Cancer Res 2019;25:5351-63. [PMID: 31186314 DOI: 10.1158/1078-0432.CCR-18-4192] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
149 Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, Qi C, Wang Q, Huang M, Zhang Y, Huang D, Bai Y, Sun F, Lee JJ, Wang Z, Wang J. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2020;6:375-84. [PMID: 31876895 DOI: 10.1001/jamaoncol.2019.5367] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 36.5] [Reference Citation Analysis]
150 Swami N, Hwang WL, Guo JA, Hoffman H, Abramowitz MC, Elbakouny Z, Beltran H, Chipidza F, Choueiri T, Pra AD, Huang F, Kaochar S, Kantoff P, Kim DW, Kishan AU, Kobetz E, Marinac C, Mucci LA, Muralidhar V, Pollack A, Sanford NN, Schaeffer EM, Spratt DE, Zhao SG, Rebbeck TR, Nguyen PL, Feng FY, Mahal BA, Alshalalfa M. Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genet 2021;258-259:61-8. [PMID: 34551377 DOI: 10.1016/j.cancergen.2021.08.004] [Reference Citation Analysis]
151 Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O'Brien ET 3rd, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY. HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest 2013;123:2078-93. [PMID: 23563312 DOI: 10.1172/JCI66715] [Cited by in Crossref: 104] [Cited by in F6Publishing: 78] [Article Influence: 11.6] [Reference Citation Analysis]
152 Zamora AE, Crawford JC, Allen EK, Guo XJ, Bakke J, Carter RA, Abdelsamed HA, Moustaki A, Li Y, Chang TC, Awad W, Dallas MH, Mullighan CG, Downing JR, Geiger TL, Chen T, Green DR, Youngblood BA, Zhang J, Thomas PG. Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses. Sci Transl Med 2019;11:eaat8549. [PMID: 31243155 DOI: 10.1126/scitranslmed.aat8549] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
153 Mender I, Zhang A, Ren Z, Han C, Deng Y, Siteni S, Li H, Zhu J, Vemula A, Shay JW, Fu YX. Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. Cancer Cell 2020;38:400-411.e6. [PMID: 32619407 DOI: 10.1016/j.ccell.2020.05.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
154 Porichis F, Hart MG, Zupkosky J, Barblu L, Kwon DS, McMullen A, Brennan T, Ahmed R, Freeman GJ, Kavanagh DG, Kaufmann DE. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions. J Virol 2014;88:2508-18. [PMID: 24352453 DOI: 10.1128/JVI.02034-13] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
155 Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol 2017;28:1988-95. [PMID: 28595336 DOI: 10.1093/annonc/mdx190] [Cited by in Crossref: 151] [Cited by in F6Publishing: 147] [Article Influence: 37.8] [Reference Citation Analysis]
156 Rousset-Rouviere S, Rochigneux P, Chrétien AS, Fattori S, Gorvel L, Provansal M, Lambaudie E, Olive D, Sabatier R. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology. Biomedicines 2021;9:632. [PMID: 34199461 DOI: 10.3390/biomedicines9060632] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
157 Ishikawa E, Satou A, Nakamura M, Nakamura S, Fujishiro M. Epstein-Barr Virus Positive B-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract. Cancers (Basel) 2021;13:3815. [PMID: 34359715 DOI: 10.3390/cancers13153815] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
158 Bian Y, Liu YF, Jiang H, Meng Y, Liu F, Cao K, Zhang H, Fang X, Li J, Yu J, Feng X, Li Q, Wang L, Lu J, Shao C. Machine learning for MRI radiomics: a study predicting tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma. Abdom Radiol (NY) 2021. [PMID: 34189612 DOI: 10.1007/s00261-021-03159-9] [Reference Citation Analysis]
159 Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma. J Nucl Med 2017;58:1421-8. [PMID: 28360208 DOI: 10.2967/jnumed.116.188839] [Cited by in Crossref: 129] [Cited by in F6Publishing: 103] [Article Influence: 25.8] [Reference Citation Analysis]
160 Xu T, Chai J, Wang K, Jia Q, Liu Y, Wang Y, Xu J, Yu K, Zhao D, Ma J, Fan L, Yan Q, Guo S, Chen G, Chen Q, Xiao H, Liu F, Qi C, Liang R, Li M, Wang Z. Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma. Front Oncol 2021;11:638154. [PMID: 34221962 DOI: 10.3389/fonc.2021.638154] [Reference Citation Analysis]
161 Hartnett EG, Knight J, Radolec M, Buckanovich RJ, Edwards RP, Vlad AM. Immunotherapy Advances for Epithelial Ovarian Cancer. Cancers (Basel) 2020;12:E3733. [PMID: 33322601 DOI: 10.3390/cancers12123733] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
162 Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. J Cancer 2014;5:166-72. [PMID: 24563671 DOI: 10.7150/jca.8167] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 12.8] [Reference Citation Analysis]
163 Zheng X, Xu K, Chen L, Zhou Y, Jiang J. Prognostic value of TIM-1 expression in human non-small-cell lung cancer. J Transl Med 2019;17:178. [PMID: 31138322 DOI: 10.1186/s12967-019-1931-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
164 Bidnur S, Savdie R, Black PC. Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer 2016;2:15-25. [PMID: 27376121 DOI: 10.3233/BLC-150026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
165 Kapoor SS, Zaiss DMW. Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment. Biomedicines 2022;10:52. [DOI: 10.3390/biomedicines10010052] [Reference Citation Analysis]
166 Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunol Res 2016;4:845-57. [PMID: 27589875 DOI: 10.1158/2326-6066.CIR-16-0060] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
167 Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res. 2015;3:399-411. [PMID: 25678581 DOI: 10.1158/2326-6066.cir-14-0215] [Cited by in Crossref: 242] [Cited by in F6Publishing: 171] [Article Influence: 34.6] [Reference Citation Analysis]
168 Amin S, Baine M, Meza J, Alam M, Lin C. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. Clin Transl Radiat Oncol 2020;24:34-40. [PMID: 32613090 DOI: 10.1016/j.ctro.2020.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
169 Frebel H, Oxenius A. The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses. Trends Immunol 2013;34:193-9. [PMID: 23333205 DOI: 10.1016/j.it.2012.12.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
170 Liu J, Xu W, Li S, Sun R, Cheng W. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database. Int J Med Sci 2020;17:3200-13. [PMID: 33173439 DOI: 10.7150/ijms.50491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
171 Peng W, Lizée G, Hwu P. Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. Oncoimmunology 2013;2:e22691. [PMID: 23524510 DOI: 10.4161/onci.22691] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
172 Tomela K, Pietrzak B, Schmidt M, Mackiewicz A. The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. Life (Basel) 2020;10:E219. [PMID: 32992737 DOI: 10.3390/life10100219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Rodriguez GM, Galpin KJC, McCloskey CW, Vanderhyden BC. The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy. Cancers (Basel) 2018;10:E242. [PMID: 30042343 DOI: 10.3390/cancers10080242] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 13.0] [Reference Citation Analysis]
174 Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015;3:11. [PMID: 25901283 DOI: 10.1186/s40425-015-0057-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 174] [Article Influence: 26.3] [Reference Citation Analysis]
175 Sathianathen NJ, Krishna S, Anderson JK, Weight CJ, Gupta S, Konety BR, Griffith TS. The current status of immunobased therapies for metastatic renal-cell carcinoma. Immunotargets Ther 2017;6:83-93. [PMID: 29255699 DOI: 10.2147/ITT.S134850] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
176 Ji S, Lee J, Lee ES, Kim DH, Sin JI. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. Hum Vaccin Immunother 2021;17:1910-22. [PMID: 33522416 DOI: 10.1080/21645515.2020.1866951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
177 Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014;32:2248-2254. [PMID: 24958825 DOI: 10.1200/jco.2013.52.1377] [Cited by in Crossref: 144] [Cited by in F6Publishing: 81] [Article Influence: 18.0] [Reference Citation Analysis]
178 Aldarouish M, Wang C. Trends and advances in tumor immunology and lung cancer immunotherapy. J Exp Clin Cancer Res 2016;35:157. [PMID: 27686848 DOI: 10.1186/s13046-016-0439-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
179 Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, Pawelec G, Garbe C, Weide B. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clin Cancer Res 2016;22:2908-18. [PMID: 26787752 DOI: 10.1158/1078-0432.CCR-15-2412] [Cited by in Crossref: 318] [Cited by in F6Publishing: 200] [Article Influence: 53.0] [Reference Citation Analysis]
180 Qiu YF, Liu ZG, Yang WJ, Zhao Y, Tang J, Tang WZ, Jin Y, Li F, Zhong R, Wang H. Research progress in the treatment of small cell lung cancer. J Cancer 2017;8:29-38. [PMID: 28123595 DOI: 10.7150/jca.16822] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
181 Tang J, Jiang W, Liu D, Luo J, Wu X, Pan Z, Ding P, Li Y. The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability. Oncoimmunology. 2018;7:e1488566. [PMID: 30288357 DOI: 10.1080/2162402x.2018.1488566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
182 Wages NA, Chiuzan C, Panageas KS. Design considerations for early-phase clinical trials of immune-oncology agents. J Immunother Cancer 2018;6:81. [PMID: 30134959 DOI: 10.1186/s40425-018-0389-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
183 Kosaka N, Yoshioka Y, Fujita Y, Ochiya T. Versatile roles of extracellular vesicles in cancer. J Clin Invest. 2016;126:1163-1172. [PMID: 26974161 DOI: 10.1172/jci81130] [Cited by in Crossref: 165] [Cited by in F6Publishing: 110] [Article Influence: 27.5] [Reference Citation Analysis]
184 Zhang H, Watanabe R, Berry GJ, Vaglio A, Liao YJ, Warrington KJ, Goronzy JJ, Weyand CM. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A 2017;114:E970-9. [PMID: 28115719 DOI: 10.1073/pnas.1616848114] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 20.8] [Reference Citation Analysis]
185 Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 2018;128:805-15. [PMID: 29337305 DOI: 10.1172/JCI96113] [Cited by in Crossref: 207] [Cited by in F6Publishing: 147] [Article Influence: 51.8] [Reference Citation Analysis]
186 Ya Z, Hailemichael Y, Overwijk W, Restifo NP. Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol 2015;108:20.1.1-20.1.43. [PMID: 25640991 DOI: 10.1002/0471142735.im2001s108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
187 Nasr R, Shamseddine A, Mukherji D, Nassar F, Temraz S. The Crosstalk between Microbiome and Immune Response in Gastric Cancer. Int J Mol Sci 2020;21:E6586. [PMID: 32916853 DOI: 10.3390/ijms21186586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
188 Cooper ZA, Frederick DT, Ahmed Z, Wargo JA. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. Oncoimmunology 2013;2:e24320. [PMID: 23762807 DOI: 10.4161/onci.24320] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
189 Mairinger F, Bankfalvi A, Schmid KW, Mairinger E, Mach P, Walter RF, Borchert S, Kasimir-Bauer S, Kimmig R, Buderath P. Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response. Cancer Manag Res 2019;11:9571-83. [PMID: 31814759 DOI: 10.2147/CMAR.S219872] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
190 Ware MB, El-Rayes BF, Lesinski GB. Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer. J Immunother Cancer 2020;8:e001100. [PMID: 32843336 DOI: 10.1136/jitc-2020-001100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Park JH, Ameri AH, Dempsey KE, Conrad DN, Kem M, Mino-Kenudson M, Demehri S. Nuclear IL-33/SMAD signaling axis promotes cancer development in chronic inflammation. EMBO J 2021;40:e106151. [PMID: 33616251 DOI: 10.15252/embj.2020106151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
192 Tanaka K, Miyata H, Sugimura K, Kanemura T, Hamada-Uematsu M, Mizote Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y, Tahara H. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Sci 2016;107:726-33. [PMID: 27015293 DOI: 10.1111/cas.12938] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
193 Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol. 2013;25:230-237. [PMID: 23414607 DOI: 10.1016/j.coi.2013.01.004] [Cited by in Crossref: 101] [Cited by in F6Publishing: 97] [Article Influence: 11.2] [Reference Citation Analysis]
194 Fontugne J, Augustin J, Pujals A, Compagnon P, Rousseau B, Luciani A, Tournigand C, Cherqui D, Azoulay D, Pawlotsky JM, Calderaro J. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 2017;8:24644-51. [PMID: 28445951 DOI: 10.18632/oncotarget.15602] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 19.5] [Reference Citation Analysis]
195 Li S, Chu X, Ye L, Ni J, Zhu Z. A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy. Transl Lung Cancer Res 2020;9:2082-96. [PMID: 33209628 DOI: 10.21037/tlcr-20-512] [Reference Citation Analysis]
196 Muth ST, Saung MT, Blair AB, Henderson MG, Thomas DL 2nd, Zheng L. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma. Cancer Lett 2021;499:99-108. [PMID: 33271264 DOI: 10.1016/j.canlet.2020.11.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
197 Yang H, Wang Y, Jia Z, Wang Y, Yang X, Wu P, Song Y, Xu H, Gu D, Chen R, Xia X, Bing Z, Gao C, Cao L, Li S, Cao Z, Liang N. Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer. Front Oncol 2021;11:537735. [PMID: 33777727 DOI: 10.3389/fonc.2021.537735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Singh BH, Gulley JL. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl 2014;16:364-71. [PMID: 24435055 DOI: 10.4103/1008-682X.122585] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
199 Dillman RO, Depriest C, McClure SE. High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines. Cancer Biother Radiopharm 2014;29:53-7. [PMID: 24380630 DOI: 10.1089/cbr.2013.1565] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
200 Housseau F, Llosa NJ. Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic. Oncoimmunology 2015;4:e1008858. [PMID: 26155426 DOI: 10.1080/2162402X.2015.1008858] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
201 Narayanan V, Weekes CD. Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol 2016; 8(4): 366-379 [PMID: 27096032 DOI: 10.4251/wjgo.v8.i4.366] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
202 Yasuma T, Toda M, Kobori H, Tada N, D'Alessandro-Gabazza CN, Gabazza EC. Subcritical Water Extracts from Agaricus blazei Murrill's Mycelium Inhibit the Expression of Immune Checkpoint Molecules and Axl Receptor. J Fungi (Basel) 2021;7:590. [PMID: 34436128 DOI: 10.3390/jof7080590] [Reference Citation Analysis]
203 Xu J, Nie H, He J, Wang X, Liao K, Tu L, Xiong Z. Using Machine Learning Modeling to Explore New Immune-Related Prognostic Markers in Non-Small Cell Lung Cancer. Front Oncol 2020;10:550002. [PMID: 33215029 DOI: 10.3389/fonc.2020.550002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
204 Calinescu AA, Kamran N, Baker G, Mineharu Y, Lowenstein PR, Castro MG. Overview of current immunotherapeutic strategies for glioma. Immunotherapy 2015;7:1073-104. [PMID: 26598957 DOI: 10.2217/imt.15.75] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
205 Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A. Immune Cell Composition in Human Non-small Cell Lung Cancer. Front Immunol 2018;9:3101. [PMID: 30774636 DOI: 10.3389/fimmu.2018.03101] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 19.7] [Reference Citation Analysis]
206 Shi X, Wu S, Sun J, Liu Y, Zeng X, Liang Z. PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer. Sci Rep 2017;7:46209. [PMID: 28387300 DOI: 10.1038/srep46209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
207 Martín-Ruiz A, Fiuza-Luces C, Martínez-Martínez E, Arias CF, Gutiérrez L, Ramírez M, Martín-Acosta P, Coronado MJ, Lucia A, Provencio M. Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model. Sci Rep 2020;10:7078. [PMID: 32341383 DOI: 10.1038/s41598-020-63796-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
208 Hebeisen M, Baitsch L, Presotto D, Baumgaertner P, Romero P, Michielin O, Speiser DE, Rufer N. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest 2013;123:1044-56. [PMID: 23391724 DOI: 10.1172/JCI65325] [Cited by in Crossref: 76] [Cited by in F6Publishing: 50] [Article Influence: 8.4] [Reference Citation Analysis]
209 Chang LS, Yan WL, Chang YW, Yeh YC, Chen HW, Leng CH, Liu SJ. Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy. Oncoimmunology 2016;5:e1095433. [PMID: 27141356 DOI: 10.1080/2162402X.2015.1095433] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
210 Wang JJ, Siu MK, Jiang YX, Leung TH, Chan DW, Wang HG, Ngan HY, Chan KK. A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer. Biomolecules 2021;11:1749. [PMID: 34944392 DOI: 10.3390/biom11121749] [Reference Citation Analysis]
211 Hoffmann M, Pantazis N, Martin GE, Hickling S, Hurst J, Meyerowitz J, Willberg CB, Robinson N, Brown H, Fisher M, Kinloch S, Babiker A, Weber J, Nwokolo N, Fox J, Fidler S, Phillips R, Frater J; SPARTAC and CHERUB Investigators. Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. PLoS Pathog 2016;12:e1005661. [PMID: 27415828 DOI: 10.1371/journal.ppat.1005661] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 14.3] [Reference Citation Analysis]
212 Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7:737. [PMID: 28389661 DOI: 10.1038/s41598-017-00462-8] [Cited by in Crossref: 296] [Cited by in F6Publishing: 288] [Article Influence: 59.2] [Reference Citation Analysis]
213 Bodhankar S, Chen Y, Lapato A, Dotson AL, Wang J, Vandenbark AA, Saugstad JA, Offner H. PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation. Stroke 2015;46:2926-34. [PMID: 26306753 DOI: 10.1161/STROKEAHA.115.010592] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
214 van den Bulk J, Verdegaal EM, de Miranda NF. Cancer immunotherapy: broadening the scope of targetable tumours. Open Biol. 2018;8. [PMID: 29875199 DOI: 10.1098/rsob.180037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 11.7] [Reference Citation Analysis]
215 Fankhauser CD, Schüffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, Hermanns T, Poyet C, Sulser T, Moch H, Wild PJ. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget 2018;9:10284-93. [PMID: 29535806 DOI: 10.18632/oncotarget.22888] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
216 van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D, Nieuwland M, Stratton MR, Kerkhoven RM, Kesmir C, Haanen JB, Kvistborg P, Schumacher TN. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013;31:e439-42. [PMID: 24043743 DOI: 10.1200/JCO.2012.47.7521] [Cited by in Crossref: 575] [Cited by in F6Publishing: 367] [Article Influence: 63.9] [Reference Citation Analysis]
217 Le DT, Jaffee EM. Harnessing immune responses in the tumor microenvironment: all signals needed. Clin Cancer Res. 2013;19:6061-6063. [PMID: 24097857 DOI: 10.1158/1078-0432.ccr-13-2424] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
218 Tang PA, Heng DY. Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep 2013;15:98-104. [PMID: 23263823 DOI: 10.1007/s11912-012-0284-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
219 Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol 2014;15:658-69. [PMID: 25096781 DOI: 10.1007/s11864-014-0305-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 6.6] [Reference Citation Analysis]
220 Maritaz C, Broutin S, Chaput N, Marabelle A, Paci A. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol 2022;15:6. [PMID: 35033167 DOI: 10.1186/s13045-021-01182-3] [Reference Citation Analysis]
221 Rubin MA. Insights into the mechanism of organ-specific cancer metastasis. Cancer Discov 2014;4:1262-4. [PMID: 25367948 DOI: 10.1158/2159-8290.CD-14-1075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
222 Tanaka Y, Murata-Hirai K, Iwasaki M, Matsumoto K, Hayashi K, Kumagai A, Nada MH, Wang H, Kobayashi H, Kamitakahara H, Okamura H, Sugie T, Minato N, Toi M, Morita CT. Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug. Cancer Sci 2018;109:587-99. [PMID: 29288540 DOI: 10.1111/cas.13491] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
223 Tsai KK, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother. 2014;10:3111-3116. [PMID: 25625924 DOI: 10.4161/21645515.2014.983409] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
224 Chandrasekaran D, Sundaram S, N K, R P. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma. Asian Pac J Cancer Prev 2019;20:2951-7. [PMID: 31653140 DOI: 10.31557/APJCP.2019.20.10.2951] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
225 Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clin Transl Med 2018;7:32. [PMID: 30294755 DOI: 10.1186/s40169-018-0210-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
226 Weiss L, Huemer F, Mlineritsch B, Greil R. Immune checkpoint blockade in ovarian cancer. Memo 2016;9:82-4. [PMID: 27429660 DOI: 10.1007/s12254-016-0267-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
227 Gedye C, Hogg D, Butler M, Joshua AM. New treatments for metastatic melanoma. CMAJ 2014;186:754-60. [PMID: 24549129 DOI: 10.1503/cmaj.130989] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
228 Nwani NG, Sima LE, Nieves-Neira W, Matei D. Targeting the Microenvironment in High Grade Serous Ovarian Cancer. Cancers (Basel) 2018;10:E266. [PMID: 30103384 DOI: 10.3390/cancers10080266] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
229 Chen YY, Ge JY, Ma D, Yu KD. Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer. Front Oncol 2020;10:570981. [PMID: 33163401 DOI: 10.3389/fonc.2020.570981] [Reference Citation Analysis]
230 Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T, Alix-Panabières C. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 2015;9:1773-82. [PMID: 26093818 DOI: 10.1016/j.molonc.2015.05.009] [Cited by in Crossref: 205] [Cited by in F6Publishing: 200] [Article Influence: 29.3] [Reference Citation Analysis]
231 Kansara M, Leong HS, Lin DM, Popkiss S, Pang P, Garsed DW, Walkley CR, Cullinane C, Ellul J, Haynes NM, Hicks R, Kuijjer ML, Cleton-Jansen AM, Hinds PW, Smyth MJ, Thomas DM. Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. J Clin Invest 2013;123:5351-60. [PMID: 24231354 DOI: 10.1172/JCI70559] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
232 Kamphorst AO, Araki K, Ahmed R. Beyond adjuvants: immunomodulation strategies to enhance T cell immunity. Vaccine 2015;33 Suppl 2:B21-8. [PMID: 26022562 DOI: 10.1016/j.vaccine.2014.12.082] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
233 Kawazoe A, Shitara K, Fukuoka S, Noguchi M, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yoshino T, Ohtsu A, Doi T. Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. Invest New Drugs 2015;33:664-70. [PMID: 25773493 DOI: 10.1007/s10637-015-0231-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
234 Okuno D, Sugiura Y, Sakamoto N, Tagod MSO, Iwasaki M, Noda S, Tamura A, Senju H, Umeyama Y, Yamaguchi H, Suematsu M, Morita CT, Tanaka Y, Mukae H. Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells. Front Immunol 2020;11:1405. [PMID: 32793196 DOI: 10.3389/fimmu.2020.01405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Xiao Y, Yu Y, Gao D, Jin W, Jiang P, Li Y, Wang C, Song Y, Zhan P, Gu F, Zhang C, Wang B, Chen Y, Du B, Zhang R. Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer. Front Oncol 2019;9:236. [PMID: 31024841 DOI: 10.3389/fonc.2019.00236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
236 Wang C, Li M, Wei R, Wu J. Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma. J Bone Oncol 2020;25:100332. [PMID: 33145154 DOI: 10.1016/j.jbo.2020.100332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
237 Pike R, Thomas N, Workman S, Ambrose L, Guzman D, Sivakumaran S, Johnson M, Thorburn D, Harber M, Chain B, Stauss HJ. PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients. Front Immunol 2016;7:126. [PMID: 27148254 DOI: 10.3389/fimmu.2016.00126] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
238 Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun 2017;8:14754. [PMID: 28345650 DOI: 10.1038/ncomms14754] [Cited by in Crossref: 136] [Cited by in F6Publishing: 144] [Article Influence: 27.2] [Reference Citation Analysis]
239 Aust S, Felix S, Auer K, Bachmayr-Heyda A, Kenner L, Dekan S, Meier SM, Gerner C, Grimm C, Pils D. Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer. Sci Rep 2017;7:42929. [PMID: 28266500 DOI: 10.1038/srep42929] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
240 Yang B, Liu T, Qu Y, Liu H, Zheng SG, Cheng B, Sun J. Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers. Front Oncol 2018;8:563. [PMID: 30547012 DOI: 10.3389/fonc.2018.00563] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
241 AiErken N, Shi HJ, Zhou Y, Shao N, Zhang J, Shi Y, Yuan ZY, Lin Y. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. Int J Biol Sci 2017;13:1172-9. [PMID: 29104508 DOI: 10.7150/ijbs.20868] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
242 Shi H, Li K, Ni Y, Liang X, Zhao X. Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Front Cell Dev Biol 2021;9:707198. [PMID: 34336860 DOI: 10.3389/fcell.2021.707198] [Reference Citation Analysis]
243 Leite KR, Reis ST, Junior JP, Zerati M, Gomes Dde O, Camara-Lopes LH, Srougi M. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn Pathol 2015;10:189. [PMID: 26470780 DOI: 10.1186/s13000-015-0414-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 6.7] [Reference Citation Analysis]
244 Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, Lai I, Roberts IM, Sloan HL, Bhatia S, Shibuya KC, Gooley T, Desmarais C, Koelle DM, Yee C, Nghiem P. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res 2014;2:27-36. [PMID: 24432305 DOI: 10.1158/2326-6066.CIR-13-0087] [Cited by in Crossref: 62] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
245 Guo Y, Jin Y, Wang B, Liu B. Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization. Int J Mol Sci 2021;22:4766. [PMID: 33946261 DOI: 10.3390/ijms22094766] [Reference Citation Analysis]
246 Merino M, Lozano T, Casares N, Lana H, Troconiz IF, Ten Hagen TLM, Kochan G, Berraondo P, Zalba S, Garrido MJ. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. J Nanobiotechnology 2021;19:102. [PMID: 33849551 DOI: 10.1186/s12951-021-00846-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
247 Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharmacol. 2017;8:730. [PMID: 29093678 DOI: 10.3389/fphar.2017.00730] [Cited by in Crossref: 174] [Cited by in F6Publishing: 167] [Article Influence: 34.8] [Reference Citation Analysis]
248 Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22. [PMID: 24048123 DOI: 10.1038/ni.2703] [Cited by in Crossref: 1775] [Cited by in F6Publishing: 1724] [Article Influence: 197.2] [Reference Citation Analysis]
249 Ho TTB, Nasti A, Seki A, Komura T, Inui H, Kozaka T, Kitamura Y, Shiba K, Yamashita T, Yamashita T, Mizukoshi E, Kawaguchi K, Wada T, Honda M, Kaneko S, Sakai Y. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. J Immunother Cancer 2020;8:e001367. [PMID: 33188035 DOI: 10.1136/jitc-2020-001367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
250 Hashimoto M, Im SJ, Araki K, Ahmed R. Cytokine-Mediated Regulation of CD8 T-Cell Responses During Acute and Chronic Viral Infection. Cold Spring Harb Perspect Biol 2019;11:a028464. [PMID: 29101105 DOI: 10.1101/cshperspect.a028464] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
251 Hu C, Liu X, Zeng Y, Liu J, Wu F. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clin Epigenetics 2021;13:166. [PMID: 34452630 DOI: 10.1186/s13148-021-01154-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
252 Chen J, Li H, Pang R, Huang J. Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients. Onco Targets Ther 2017;10:2003-7. [PMID: 28435290 DOI: 10.2147/OTT.S127498] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
253 Guerrero AD, Moyes JS, Cooper LJ. The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer 2014;33:421-33. [PMID: 25189715 DOI: 10.5732/cjc.014.10100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
254 Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget 2015;6:32228-43. [PMID: 26334096 DOI: 10.18632/oncotarget.4772] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
255 Francis DM, Thomas SN. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. Adv Drug Deliv Rev 2017;114:33-42. [PMID: 28455187 DOI: 10.1016/j.addr.2017.04.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
256 Lin M, Gao M, Pandalai PK, Cavnar MJ, Kim J. An Organotypic Microcosm for the Pancreatic Tumor Microenvironment. Cancers (Basel) 2020;12:E811. [PMID: 32231028 DOI: 10.3390/cancers12040811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
257 Li Z, Chen L, Rubinstein MP. Cancer immunotherapy: are we there yet? Exp Hematol Oncol 2013;2:33. [PMID: 24326015 DOI: 10.1186/2162-3619-2-33] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
258 Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R. Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. Clin Cancer Res 2018;24:1785-94. [PMID: 29212781 DOI: 10.1158/1078-0432.CCR-17-1970] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 5.4] [Reference Citation Analysis]
259 Chen YF, Wang YH, Lei CS, Changou CA, Davis ME, Yen Y. Host immune response to anti-cancer camptothecin conjugated cyclodextrin-based polymers. J Biomed Sci 2019;26:85. [PMID: 31647037 DOI: 10.1186/s12929-019-0583-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
260 Sun X, Yan X, Zhuo W, Gu J, Zuo K, Liu W, Liang L, Gan Y, He G, Wan H, Gou X, Shi H, Hu J. PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations. Int J Mol Sci 2018;19:E1984. [PMID: 29986511 DOI: 10.3390/ijms19071984] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
261 Libutti SK. Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy’s smart bombs. Cancer Gene Ther. 2015;22:63. [PMID: 25753044 DOI: 10.1038/cgt.2015.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
262 Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai M, Hellstrom I, Hellstrom KE, Guo Y. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 2013;8:e84927. [PMID: 24367702 DOI: 10.1371/journal.pone.0084927] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
263 Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara K, Sakaguchi S, Nishikawa H. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A 2019;116:9999-10008. [PMID: 31028147 DOI: 10.1073/pnas.1822001116] [Cited by in Crossref: 254] [Cited by in F6Publishing: 246] [Article Influence: 84.7] [Reference Citation Analysis]
264 Goeppert B, Frauenschuh L, Zucknick M, Stenzinger A, Andrulis M, Klauschen F, Joehrens K, Warth A, Renner M, Mehrabi A. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer. 2013;109:2665-2674. [PMID: 24136146 DOI: 10.1038/bjc.2013.610] [Cited by in Crossref: 105] [Cited by in F6Publishing: 104] [Article Influence: 11.7] [Reference Citation Analysis]
265 Mejia I, Bodapati S, Chen KT, Díaz B. Pancreatic Adenocarcinoma Invasiveness and the Tumor Microenvironment: From Biology to Clinical Trials. Biomedicines 2020;8:E401. [PMID: 33050151 DOI: 10.3390/biomedicines8100401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
266 Eggermont A, Robert C, Soria JC, Zitvogel L. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. Oncoimmunology. 2014;3:e27560. [PMID: 24719793 DOI: 10.4161/onci.27560] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
267 Chen X, Chen X, Gao J, Yang H, Duan Y, Feng Y, He X, Gong X, Wang H, Wu X, Chang J. Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-γ. Front Pharmacol 2019;10:898. [PMID: 31456687 DOI: 10.3389/fphar.2019.00898] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
268 Jamil ML, Deebajah M, Sood A, Alanee S. Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study. BMJ Open 2019;9:e027066. [PMID: 31796469 DOI: 10.1136/bmjopen-2018-027066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
269 Yeo KP, Angeli V. Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity. Front Immunol 2017;8:83. [PMID: 28220121 DOI: 10.3389/fimmu.2017.00083] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
270 Kumar-Sinha C, Chinnaiyan AM. Precision oncology in the age of integrative genomics. Nat Biotechnol 2018;36:46-60. [PMID: 29319699 DOI: 10.1038/nbt.4017] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 15.5] [Reference Citation Analysis]
271 Speiser DE, Utzschneider DT, Oberle SG, Münz C, Romero P, Zehn D. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol 2014;14:768-74. [PMID: 25257362 DOI: 10.1038/nri3740] [Cited by in Crossref: 163] [Cited by in F6Publishing: 154] [Article Influence: 20.4] [Reference Citation Analysis]
272 Guo CX, Huang X, Xu J, Zhang XZ, Shen YN, Liang TB, Bai XL. Combined targeted therapy and immunotherapy for cancer treatment. World J Clin Cases 2021; 9(26): 7643-7652 [PMID: 34621816 DOI: 10.12998/wjcc.v9.i26.7643] [Reference Citation Analysis]
273 Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, Hernandez C, Fernandez G, Garcia-Granda MJ, Blanco E, Vera R, Kochan G, Escors D. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? Front Pharmacol 2020;11:441. [PMID: 32317979 DOI: 10.3389/fphar.2020.00441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
274 Hou YC, Chao YJ, Hsieh MH, Tung HL, Wang HC, Shan YS. Low CD8⁺ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44⁺/CD133⁺ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer. Cancers (Basel) 2019;11:E541. [PMID: 30991694 DOI: 10.3390/cancers11040541] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
275 Pal SK, Hu A, Figlin RA. A new age for vaccine therapy in renal cell carcinoma. Cancer J 2013;19:365-70. [PMID: 23867519 DOI: 10.1097/PPO.0b013e31829d74b4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
276 Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer DA, Chughtai KA, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi SW. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant 2016;51:511-20. [PMID: 26191952 DOI: 10.1038/bmt.2015.170] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
277 Zhu SK, Xu T, Wang R. Prospects and challenges of immunotherapy for pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2019; 27(1): 6-12 [DOI: 10.11569/wcjd.v27.i1.6] [Reference Citation Analysis]
278 Gottschalk C, Damuzzo V, Gotot J, Kroczek RA, Yagita H, Murphy KM, Knolle PA, Ludwig-Portugall I, Kurts C. Batf3-dependent dendritic cells in the renal lymph node induce tolerance against circulating antigens. J Am Soc Nephrol 2013;24:543-9. [PMID: 23411785 DOI: 10.1681/ASN.2012101022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
279 Martin Lluesma S, Wolfer A, Harari A, Kandalaft LE. Cancer Vaccines in Ovarian Cancer: How Can We Improve? Biomedicines 2016;4:E10. [PMID: 28536377 DOI: 10.3390/biomedicines4020010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
280 Schmidt TL, Negrin RS, Contag CH. A killer choice for cancer immunotherapy. Immunol Res 2014;58:300-6. [PMID: 24791943 DOI: 10.1007/s12026-014-8507-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
281 Ji M, Liu Y, Li Q, Li X, Ning Z, Zhao W, Shi H, Jiang J, Wu C. PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Cancer Biol Ther 2016;17:407-13. [PMID: 26954523 DOI: 10.1080/15384047.2016.1156256] [Cited by in Crossref: 60] [Cited by in F6Publishing: 70] [Article Influence: 10.0] [Reference Citation Analysis]
282 Mei L, Du W, Ma WW. Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. J Gastrointest Oncol. 2016;7:487-494. [PMID: 27284483 DOI: 10.21037/jgo.2016.03.03] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
283 Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol. 2013;10:256-266. [PMID: 23546521 DOI: 10.1038/nrclinonc.2013.42] [Cited by in Crossref: 222] [Cited by in F6Publishing: 215] [Article Influence: 24.7] [Reference Citation Analysis]
284 Qin Q, Nan X, Miller T, Fisher R, Teh B, Pandita S, Farach AM, Pingali SR, Pandita RK, Butler EB, Pandita TK, Iyer SP. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma. Radiat Res 2018;190:322-9. [PMID: 29949442 DOI: 10.1667/RR15048.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
285 White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, Potter EA, Ardern-Jones MR, Verbeek JS, Johnson PW, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 2015;27:138-48. [PMID: 25500122 DOI: 10.1016/j.ccell.2014.11.001] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 11.9] [Reference Citation Analysis]
286 Oliveira-Costa JP, de Carvalho AF, da Silveira da GG, Amaya P, Wu Y, Park KJ, Gigliola MP, Lustberg M, Buim ME, Ferreira EN, Kowalski LP, Chalmers JJ, Soares FA, Carraro DM, Ribeiro-Silva A. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget 2015;6:20902-20. [PMID: 26041877 DOI: 10.18632/oncotarget.3939] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 10.8] [Reference Citation Analysis]
287 Spranger S, Gajewski T. Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer 2013;1:16. [PMID: 24829752 DOI: 10.1186/2051-1426-1-16] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
288 Lekka K, Tzitzi E, Giakoustidis A, Papadopoulos V, Giakoustidis D. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg 2019;23:97-108. [PMID: 31225409 DOI: 10.14701/ahbps.2019.23.2.97] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
289 Saung MT, Muth S, Ding D, Thomas DL 2nd, Blair AB, Tsujikawa T, Coussens L, Jaffee EM, Zheng L. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 2018;6:118. [PMID: 30424804 DOI: 10.1186/s40425-018-0435-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
290 Meireson A, Chevolet I, Hulstaert E, Ferdinande L, Ost P, Geboes K, De Man M, Van de Putte D, Verset L, Kruse V, Demetter P, Brochez L. Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile. Oncotarget 2018;9:25216-24. [PMID: 29861865 DOI: 10.18632/oncotarget.25393] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
291 Shafirstein G, Battoo A, Harris K, Baumann H, Gollnick SO, Lindenmann J, Nwogu CE. Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions. Ann Am Thorac Soc 2016;13:265-75. [PMID: 26646726 DOI: 10.1513/AnnalsATS.201509-650FR] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
292 Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou-Gharios G, Nakamura H, Kawashiri S. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol. 2017;50:41-48. [PMID: 27922697 DOI: 10.3892/ijo.2016.3785] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
293 Huffaker TB, Lee SH, Tang WW, Wallace JA, Alexander M, Runtsch MC, Larsen DK, Thompson J, Ramstead AG, Voth WP, Hu R, Round JL, Williams MA, O'Connell RM. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. J Biol Chem 2017;292:18530-41. [PMID: 28912267 DOI: 10.1074/jbc.M117.808121] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 8.4] [Reference Citation Analysis]
294 Torphy RJ, Zhu Y, Schulick RD. Immunotherapy for pancreatic cancer: Barriers and breakthroughs. Ann Gastroenterol Surg 2018;2:274-81. [PMID: 30003190 DOI: 10.1002/ags3.12176] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 15.5] [Reference Citation Analysis]
295 Popovic LS, Matovina-Brko G, Popovic M. Checkpoint inhibitors in the treatment of urological malignancies. ESMO Open 2017;2:e000165. [PMID: 28761743 DOI: 10.1136/esmoopen-2017-000165] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
296 Lian S, Xie R, Ye Y, Lu Y, Cheng Y, Xie X, Li S, Jia L. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. Sci Rep 2019;9:4532. [PMID: 30872703 DOI: 10.1038/s41598-019-40241-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
297 Nguyen L, Schilling D, Dobiasch S, Raulefs S, Santiago Franco M, Buschmann D, Pfaffl MW, Schmid TE, Combs SE. The Emerging Role of miRNAs for the Radiation Treatment of Pancreatic Cancer. Cancers (Basel) 2020;12:E3703. [PMID: 33317198 DOI: 10.3390/cancers12123703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
298 Liu YX, Wang XS, Wang YF, Hu XC, Yan JQ, Zhang YL, Wang W, Yang RJ, Feng YY, Gao SG. Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis. Onco Targets Ther. 2016;9:2649-2654. [PMID: 27226727 DOI: 10.2147/ott.s102616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.5] [Reference Citation Analysis]
299 Kimbara S, Kondo S. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol 2016; 22(33): 7440-7452 [PMID: 27672267 DOI: 10.3748/wjg.v22.i33.7440] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
300 Berrien-Elliott MM, Jackson SR, Meyer JM, Rouskey CJ, Nguyen TL, Yagita H, Greenberg PD, DiPaolo RJ, Teague RM. Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res 2013;73:605-16. [PMID: 23188506 DOI: 10.1158/0008-5472.CAN-12-2179] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
301 García F, Plana M, Climent N, León A, Gatell JM, Gallart T. Dendritic cell based vaccines for HIV infection: the way ahead. Hum Vaccin Immunother 2013;9:2445-52. [PMID: 23912672 DOI: 10.4161/hv.25876] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
302 Guidance Development Review Committee., Working Group for Clinical Studies of Cancer Immunotherapy., Working Group for Effector Cell Therapy., Working Group for CMC/Non-clinical Studies., Working Group for Cancer Vaccines and Adjuvants., Working Group for Anti-immune Checkpoint Therapy and Comprehensive Cancer Immunotherapy., Biostatistics Subcommittee. 2015 Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Sci 2015;106:1761-71. [PMID: 26767933 DOI: 10.1111/cas.12819] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
303 Bentley RT, Ahmed AU, Yanke AB, Cohen-Gadol AA, Dey M. Dogs are man's best friend: in sickness and in health. Neuro Oncol 2017;19:312-22. [PMID: 27298310 DOI: 10.1093/neuonc/now109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
304 Strickler JH, Hurwitz HI. Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Curr Oncol Rep 2014;16:363. [PMID: 24293074 DOI: 10.1007/s11912-013-0363-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
305 Delmas D, Hermetet F, Aires V. PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy. Cancers (Basel) 2021;13:4509. [PMID: 34572736 DOI: 10.3390/cancers13184509] [Reference Citation Analysis]
306 Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016;12:1247-1253. [PMID: 27485741 DOI: 10.1080/17425255.2016.1216976] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
307 Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res 2019;25:4592-602. [PMID: 30824587 DOI: 10.1158/1078-0432.CCR-18-1538] [Cited by in Crossref: 141] [Cited by in F6Publishing: 99] [Article Influence: 47.0] [Reference Citation Analysis]
308 Liao X, Zhao L, Wu S, Zheng H, Chen H, Zhang H, Wang Z, Lin Q. Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance. Oncotarget 2017;8:113287-93. [PMID: 29348907 DOI: 10.18632/oncotarget.22938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
309 Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014;3:e27297. [PMID: 24701370 DOI: 10.4161/onci.27297] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 10.5] [Reference Citation Analysis]
310 Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2015;15:45-56. [PMID: 25534622 DOI: 10.1038/nri3790] [Cited by in Crossref: 339] [Cited by in F6Publishing: 320] [Article Influence: 48.4] [Reference Citation Analysis]
311 Eriksson E, Moreno R, Milenova I, Liljenfeldt L, Dieterich LC, Christiansson L, Karlsson H, Ullenhag G, Mangsbo SM, Dimberg A, Alemany R, Loskog A. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment. Gene Ther 2017;24:92-103. [PMID: 27906162 DOI: 10.1038/gt.2016.80] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
312 Triozzi PL, Fernandez AP. The role of the immune response in merkel cell carcinoma. Cancers (Basel) 2013;5:234-54. [PMID: 24216706 DOI: 10.3390/cancers5010234] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
313 Evans VA, van der Sluis RM, Solomon A, Dantanarayana A, McNeil C, Garsia R, Palmer S, Fromentin R, Chomont N, Sékaly RP, Cameron PU, Lewin SR. Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. AIDS 2018;32:1491-7. [PMID: 29746296 DOI: 10.1097/QAD.0000000000001849] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 24.0] [Reference Citation Analysis]
314 Pu X, Zhang R, Wang L, Chen Y, Xu Y, Pataer A, Meraz IM, Zhang X, Wu S, Wu L, Su D, Mao W, Heymach JV, Roth JA, Swisher SG, Fang B. Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. J Transl Med 2018;16:328. [PMID: 30477533 DOI: 10.1186/s12967-018-1704-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
315 Chen PY, Wei KC, Liu HL. Neural immune modulation and immunotherapy assisted by focused ultrasound induced blood-brain barrier opening. Hum Vaccin Immunother 2015;11:2682-7. [PMID: 26378609 DOI: 10.1080/21645515.2015.1071749] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
316 Qiu XT, Song YC, Liu J, Wang ZM, Niu X, He J. Identification of an immune-related gene-based signature to predict prognosis of patients with gastric cancer. World J Gastrointest Oncol 2020; 12(8): 857-876 [PMID: 32879664 DOI: 10.4251/wjgo.v12.i8.857] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
317 Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik B, Galon J. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16:64. [PMID: 25853550 DOI: 10.1186/s13059-015-0620-6] [Cited by in Crossref: 280] [Cited by in F6Publishing: 270] [Article Influence: 40.0] [Reference Citation Analysis]
318 Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, Basu B, Magiera L, Johnson TI, Bax L, Gopinathan A, Isherwood C, Gallagher FA, Pawula M, Hudecova I, Gale D, Rosenfeld N, Barmpounakis P, Popa EC, Brais R, Godfrey E, Mir F, Richards FM, Fearon DT, Janowitz T, Jodrell DI. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc Natl Acad Sci U S A 2020;117:28960-70. [PMID: 33127761 DOI: 10.1073/pnas.2013644117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
319 Teng MW, Galon J, Fridman WH, Smyth MJ. From mice to humans: developments in cancer immunoediting. J Clin Invest 2015;125:3338-46. [PMID: 26241053 DOI: 10.1172/JCI80004] [Cited by in Crossref: 157] [Cited by in F6Publishing: 83] [Article Influence: 22.4] [Reference Citation Analysis]
320 McCullar B, Alloway T, Martin M. Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer. J Thorac Dis 2017;9:E540-2. [PMID: 28740692 DOI: 10.21037/jtd.2017.05.32] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
321 Lee JJ, Chu E. Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018;17:258-273. [PMID: 30072278 DOI: 10.1016/j.clcc.2018.06.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
322 Lazarus J, Maj T, Smith JJ, Perusina Lanfranca M, Rao A, D'Angelica MI, Delrosario L, Girgis A, Schukow C, Shia J, Kryczek I, Shi J, Wasserman I, Crawford H, Nathan H, Pasca Di Magliano M, Zou W, Frankel TL. Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 2018;3:121932. [PMID: 30429368 DOI: 10.1172/jci.insight.121932] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
323 Jesus VHF, Felismino TC, Barros E Silva MJ, Souza E Silva V, Riechelmann RP. Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies. Clinics (Sao Paulo) 2018;73:e510s. [PMID: 30365605 DOI: 10.6061/clinics/2018/e510s] [Reference Citation Analysis]
324 Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto M. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology 2013;2:e27010. [PMID: 24498547 DOI: 10.4161/onci.27010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
325 Girotti MR, Saturno G, Lorigan P, Marais R. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. Mol Oncol 2014;8:1140-58. [PMID: 25178978 DOI: 10.1016/j.molonc.2014.07.027] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
326 Zhang X, Ran Y, Wang K, Zhu Y, Li J. Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Des Devel Ther 2016;10:3153-61. [PMID: 27729774 DOI: 10.2147/DDDT.S115493] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
327 Fisher R, Larkin J. Individualising treatment choices in a crowded treatment algorithm. EJC Suppl 2013;11:160-8. [PMID: 26217125 DOI: 10.1016/j.ejcsup.2013.07.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
328 Keam B, Ock CY, Kim TM, Oh DY, Kang WK, Park YH, Lee J, Lee JH, Ahn YH, Kim HJ, Chang SK, Park J, Choi JY, Song YJ, Park YS. A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. Invest New Drugs 2021. [PMID: 34268711 DOI: 10.1007/s10637-021-01078-6] [Reference Citation Analysis]
329 Kim JH, Kim BS, Lee SK. Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy. Immune Netw 2020;20:e4. [PMID: 32158592 DOI: 10.4110/in.2020.20.e4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
330 Im SJ, Ha SJ. Re-defining T-Cell Exhaustion: Subset, Function, and Regulation. Immune Netw 2020;20:e2. [PMID: 32158590 DOI: 10.4110/in.2020.20.e2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
331 Hurez V, Padrón ÁS, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Clin Exp Immunol 2017;187:53-63. [PMID: 27690272 DOI: 10.1111/cei.12875] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
332 Sanmamed MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J 2014;20:256-61. [PMID: 25098285 DOI: 10.1097/PPO.0000000000000061] [Cited by in Crossref: 78] [Cited by in F6Publishing: 50] [Article Influence: 11.1] [Reference Citation Analysis]
333 Woller N, Engelskircher SA, Wirth T, Wedemeyer H. Prospects and Challenges for T Cell-Based Therapies of HCC. Cells 2021;10:1651. [PMID: 34209393 DOI: 10.3390/cells10071651] [Reference Citation Analysis]
334 Kong X, Kong Y. Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients? Onco Targets Ther 2017;10:1335-44. [PMID: 28280368 DOI: 10.2147/OTT.S120341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
335 Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res 2015;3:1148-57. [PMID: 26014098 DOI: 10.1158/2326-6066.CIR-15-0059] [Cited by in Crossref: 249] [Cited by in F6Publishing: 151] [Article Influence: 35.6] [Reference Citation Analysis]
336 Boichard A, Tsigelny IF, Kurzrock R. High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. Oncoimmunology 2017;6:e1284719. [PMID: 28405512 DOI: 10.1080/2162402X.2017.1284719] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
337 Ørskov AD, Treppendahl MB, Skovbo A, Holm MS, Friis LS, Hokland M, Grønbæk K. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget 2015;6:9612-26. [PMID: 25823822 DOI: 10.18632/oncotarget.3324] [Cited by in Crossref: 109] [Cited by in F6Publishing: 108] [Article Influence: 18.2] [Reference Citation Analysis]
338 Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 2015;15:361-70. [PMID: 25998715 DOI: 10.1038/nrc3930] [Cited by in Crossref: 345] [Cited by in F6Publishing: 312] [Article Influence: 49.3] [Reference Citation Analysis]
339 Dai M, Yip YY, Hellstrom I, Hellstrom KE. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res 2015;21:1127-38. [PMID: 25142145 DOI: 10.1158/1078-0432.CCR-14-1339] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
340 Schultheis A, Wolf J, Büttner R. [Lung cancer. Molecular pathology and personalized therapy]. Internist (Berl) 2013;54:179-80, 182-7. [PMID: 23371257 DOI: 10.1007/s00108-012-3151-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
341 Yang J, Hu G. Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma. Oncol Lett 2019;17:3382-6. [PMID: 30867773 DOI: 10.3892/ol.2019.9982] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
342 Wang M, Busuttil RA, Pattison S, Neeson PJ, Boussioutas A. Immunological battlefield in gastric cancer and role of immunotherapies. World J Gastroenterol 2016; 22(28): 6373-6384 [PMID: 27605873 DOI: 10.3748/wjg.v22.i28.6373] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
343 Chen G, Kim YH, Li H, Luo H, Liu DL, Zhang ZJ, Lay M, Chang W, Zhang YQ, Ji RR. PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. Nat Neurosci 2017;20:917-26. [PMID: 28530662 DOI: 10.1038/nn.4571] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 15.2] [Reference Citation Analysis]
344 Osawa Y, Kojika E, Nishikawa K, Kimura M, Osakaya S, Miyauchi H, Kanto T, Kawakami Y, Kimura K. Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers. Oncotarget 2019;10:3013-26. [PMID: 31105882 DOI: 10.18632/oncotarget.26892] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
345 Wartewig T, Kurgyis Z, Keppler S, Pechloff K, Hameister E, Öllinger R, Maresch R, Buch T, Steiger K, Winter C, Rad R, Ruland J. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature 2017;552:121-5. [PMID: 29143824 DOI: 10.1038/nature24649] [Cited by in Crossref: 116] [Cited by in F6Publishing: 112] [Article Influence: 23.2] [Reference Citation Analysis]
346 Lutz-Nicoladoni C, Wolf D, Sopper S. Modulation of Immune Cell Functions by the E3 Ligase Cbl-b. Front Oncol 2015;5:58. [PMID: 25815272 DOI: 10.3389/fonc.2015.00058] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
347 Tomasello G, Ghidini M, Liguigli W, Ratti M, Toppo L, Passalacqua R. Targeted therapies in gastric cancer treatment: where we are and where we are going. Invest New Drugs. 2016;34:378-393. [PMID: 26873643 DOI: 10.1007/s10637-016-0330-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
348 Ruscetti M, Morris JP 4th, Mezzadra R, Russell J, Leibold J, Romesser PB, Simon J, Kulick A, Ho YJ, Fennell M, Li J, Norgard RJ, Wilkinson JE, Alonso-Curbelo D, Sridharan R, Heller DA, de Stanchina E, Stanger BZ, Sherr CJ, Lowe SW. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell 2020;181:424-441.e21. [PMID: 32234521 DOI: 10.1016/j.cell.2020.03.008] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 31.5] [Reference Citation Analysis]
349 Yu Y, Huang S, Chen J, Yu F, Zhang L, Xiang X, Deng J, Fang Z, Li J, Xiong J. An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers. Cancer Control 2021;28:10732748211017165. [PMID: 33982628 DOI: 10.1177/10732748211017165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24:26. [PMID: 28376884 DOI: 10.1186/s12929-017-0329-9] [Cited by in Crossref: 261] [Cited by in F6Publishing: 266] [Article Influence: 52.2] [Reference Citation Analysis]
351 Lee SH, Danishmalik SN, Sin JI. DNA vaccines, electroporation and their applications in cancer treatment. Hum Vaccin Immunother 2015;11:1889-900. [PMID: 25984993 DOI: 10.1080/21645515.2015.1035502] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
352 Batista IA, Melo SA. Exosomes and the Future of Immunotherapy in Pancreatic Cancer. Int J Mol Sci. 2019;20. [PMID: 30699928 DOI: 10.3390/ijms20030567] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
353 Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer. 2014;111:2214-2219. [PMID: 25211661 DOI: 10.1038/bjc.2014.348] [Cited by in Crossref: 96] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
354 Shinagawa T, Ito H, Sakai Y, Mikami S, Oe H, Taga M, Yokoyama O. Remarkable effect of presurgical nivolumab on originally inoperable papillary renal cell carcinoma with tumor thrombus in inferior vena cava. Int Cancer Conf J 2019;8:170-4. [PMID: 31559117 DOI: 10.1007/s13691-019-00379-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
355 van Doorn DJ, Takkenberg RB, Klümpen HJ. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals (Basel) 2020;14:3. [PMID: 33374927 DOI: 10.3390/ph14010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
356 Walz S, Stickel JS, Kowalewski DJ, Schuster H, Weisel K, Backert L, Kahn S, Nelde A, Stroh T, Handel M, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood 2015;126:1203-13. [PMID: 26138685 DOI: 10.1182/blood-2015-04-640532] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 9.7] [Reference Citation Analysis]
357 Beswick EJ, Johnson JR, Saada JI, Humen M, House J, Dann S, Qiu S, Brasier AR, Powell DW, Reyes VE, Pinchuk IV. TLR4 activation enhances the PD-L1-mediated tolerogenic capacity of colonic CD90+ stromal cells. J Immunol 2014;193:2218-29. [PMID: 25070848 DOI: 10.4049/jimmunol.1203441] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
358 Inamura K, Takazawa Y, Inoue Y, Yokouchi Y, Kobayashi M, Saiura A, Shibutani T, Ishikawa Y. Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer. J Clin Med 2018;7:E172. [PMID: 29996538 DOI: 10.3390/jcm7070172] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
359 Trebska-McGowan K, Chaib M, Alvarez MA, Kansal R, Pingili AK, Shibata D, Makowski L, Glazer ES. TGF-β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg 2021. [PMID: 34260016 DOI: 10.1007/s11605-021-05087-x] [Reference Citation Analysis]
360 Park JS, Withers SS, Modiano JF, Kent MS, Chen M, Luna JI, Culp WTN, Sparger EE, Rebhun RB, Monjazeb AM, Murphy WJ, Canter RJ. Canine cancer immunotherapy studies: linking mouse and human. J Immunother Cancer 2016;4:97. [PMID: 28031824 DOI: 10.1186/s40425-016-0200-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
361 Kroll AV, Jiang Y, Zhou J, Holay M, Fang RH, Zhang L. Biomimetic Nanoparticle Vaccines for Cancer Therapy. Adv Biosyst 2019;3:e1800219. [PMID: 31728404 DOI: 10.1002/adbi.201800219] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
362 D'Souza NM, Fang P, Logan J, Yang J, Jiang W, Li J. Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. Front Oncol 2016;6:212. [PMID: 27774435 DOI: 10.3389/fonc.2016.00212] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
363 Perea F, Sánchez-Palencia A, Gómez-Morales M, Bernal M, Concha Á, García MM, González-Ramírez AR, Kerick M, Martin J, Garrido F, Ruiz-Cabello F, Aptsiauri N. HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. Oncotarget 2018;9:4120-33. [PMID: 29423109 DOI: 10.18632/oncotarget.23469] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
364 Bazzichetto C, Conciatori F, Luchini C, Simionato F, Santoro R, Vaccaro V, Corbo V, Falcone I, Ferretti G, Cognetti F, Melisi D, Scarpa A, Ciuffreda L, Milella M. From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. Cells 2020;9:E309. [PMID: 32012917 DOI: 10.3390/cells9020309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
365 Lina TT, Alzahrani S, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE. Immune evasion strategies used by Helicobacter pyloriWorld J Gastroenterol 2014; 20(36): 12753-12766 [PMID: 25278676 DOI: 10.3748/wjg.v20.i36.12753] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
366 Hickmott L, De La Peña H, Turner H, Ahmed F, Protheroe A, Grossman A, Gupta A. Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature. Target Oncol 2017;12:235-41. [PMID: 28255845 DOI: 10.1007/s11523-017-0480-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
367 Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F. Re-evaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection. PLoS One 2013;8:e60186. [PMID: 23555918 DOI: 10.1371/journal.pone.0060186] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
368 Jiang X, Seo YD, Chang JH, Coveler A, Nigjeh EN, Pan S, Jalikis F, Yeung RS, Crispe IN, Pillarisetty VG. Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment. Oncoimmunology 2017;6:e1333210. [PMID: 28811976 DOI: 10.1080/2162402X.2017.1333210] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
369 Kuang M, Cheng J, Zhang C, Feng L, Xu X, Zhang Y, Zu M, Cui J, Yu H, Zhang K, Yang A, Cheng S. A novel signature for stratifying the molecular heterogeneity of the tissue-infiltrating T-cell receptor repertoire reflects gastric cancer prognosis. Sci Rep 2017;7:7762. [PMID: 28798410 DOI: 10.1038/s41598-017-08289-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
370 Choi SH, Seong J. Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma? Yonsei Med J. 2018;59:912-922. [PMID: 30187697 DOI: 10.3349/ymj.2018.59.8.912] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
371 Qian H, Li H, Xie J, Lu X, Li F, Wang W, Tang X, Shi M, Jiang L, Li H, Chen H, Peng C, Xu Z, Deng X, Shen B. Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer. Front Cell Dev Biol 2021;9:682261. [PMID: 34249934 DOI: 10.3389/fcell.2021.682261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 2018;31:214-34. [PMID: 29192647 DOI: 10.1038/modpathol.2017.156] [Cited by in Crossref: 136] [Cited by in F6Publishing: 138] [Article Influence: 27.2] [Reference Citation Analysis]
373 Jomrich G, Silberhumer GR, Marian B, Beer A, Müllauer L. Programmed death-ligand 1 expression in rectal cancer. Eur Surg 2016;48:352-6. [PMID: 28058043 DOI: 10.1007/s10353-016-0447-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
374 Morse CB, Elvin JA, Gay LM, Liao JB. Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. Gynecol Oncol Rep 2017;21:78-80. [PMID: 28736741 DOI: 10.1016/j.gore.2017.06.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
375 McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016;2:46-54. [PMID: 26562159 DOI: 10.1001/jamaoncol.2015.3638] [Cited by in Crossref: 431] [Cited by in F6Publishing: 460] [Article Influence: 71.8] [Reference Citation Analysis]
376 Brahm CG, van Linde ME, Enting RH, Schuur M, Otten RHJ, Heymans MW, Verheul HMW, Walenkamp AME. The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review. Cancers (Basel) 2020;12:E586. [PMID: 32143288 DOI: 10.3390/cancers12030586] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
377 Zhong JH, Luo CP, Zhang CY, Li LQ. Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients. J Hepatocell Carcinoma 2017;4:11-3. [PMID: 28116284 DOI: 10.2147/JHC.S122807] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
378 Mishra DK, Rocha HJ, Miller R, Kim MP. Immune cells inhibit the tumor metastasis in the 4D cellular lung model by reducing the number of live circulating tumor cells. Sci Rep 2018;8:16569. [PMID: 30410108 DOI: 10.1038/s41598-018-34983-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
379 Wang F, Yang S, Palmer N, Fox K, Kohane IS, Liao KP, Yu KH, Kou SC. Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types. NPJ Precis Oncol 2021;5:82. [PMID: 34508179 DOI: 10.1038/s41698-021-00223-x] [Reference Citation Analysis]
380 Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol. 2017;8:1597. [PMID: 29255458 DOI: 10.3389/fimmu.2017.01597] [Cited by in Crossref: 116] [Cited by in F6Publishing: 114] [Article Influence: 23.2] [Reference Citation Analysis]
381 Chen TT. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. J Natl Cancer Inst 2015;107:djv156. [PMID: 26113579 DOI: 10.1093/jnci/djv156] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
382 Zhu Z, Dong W. Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma. Onco Targets Ther 2018;11:1563-70. [PMID: 29593422 DOI: 10.2147/OTT.S160493] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
383 Mirlekar B, Michaud D, Searcy R, Greene K, Pylayeva-Gupta Y. IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 2018;6:1014-24. [PMID: 29980536 DOI: 10.1158/2326-6066.CIR-17-0710] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
384 Lavoué V, Foucher F, Henno S, Bauville E, Catros V, Cabillic F, Levêque J. [Immunotherapy in epithelial ovarian carcinoma: hope and reality]. J Gynecol Obstet Biol Reprod (Paris) 2014;43:198-210. [PMID: 24230482 DOI: 10.1016/j.jgyn.2013.10.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
385 Cheng W, Fu D, Xu F, Zhang Z. Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. Oncogenesis 2018;7:2. [PMID: 29358573 DOI: 10.1038/s41389-017-0013-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
386 Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology 2016;5:e1106127. [PMID: 26942094 DOI: 10.1080/2162402X.2015.1106127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
387 Jiang H, Cui N, Yang L, Liu C, Yue L, Guo L, Wang H, Shao Z. Altered follicular helper T cell impaired antibody production in a murine model of myelodysplastic syndromes. Oncotarget 2017;8:98270-9. [PMID: 29228688 DOI: 10.18632/oncotarget.21548] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
388 Albrecht T, Brinkmann F, Albrecht M, Lonsdorf AS, Mehrabi A, Hoffmann K, Kulu Y, Charbel A, Vogel MN, Rupp C, Köhler B, Springfeld C, Schirmacher P, Roessler S, Goeppert B. Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer. Cancers (Basel) 2021;13:1682. [PMID: 33918309 DOI: 10.3390/cancers13071682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
389 Liu M, Gao Y, Yuan Y, Shi S, Wu J, Tian J, Zhang J. An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers. Biomed Pharmacother 2021;143:112238. [PMID: 34649362 DOI: 10.1016/j.biopha.2021.112238] [Reference Citation Analysis]
390 Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94:41-53. [PMID: 23667165 DOI: 10.1189/jlb.1212631] [Cited by in Crossref: 206] [Cited by in F6Publishing: 192] [Article Influence: 22.9] [Reference Citation Analysis]
391 Li Z, Wang Y, Shen Y, Qian C, Oupicky D, Sun M. Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy. Sci Adv 2020;6:eaaz9240. [PMID: 32440550 DOI: 10.1126/sciadv.aaz9240] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
392 Gorchs L, Fernández Moro C, Bankhead P, Kern KP, Sadeak I, Meng Q, Rangelova E, Kaipe H. Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells. Front Immunol 2019;10:847. [PMID: 31068935 DOI: 10.3389/fimmu.2019.00847] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
393 Haanen JB. Immunotherapy of melanoma. EJC Suppl 2013;11:97-105. [PMID: 26217118 DOI: 10.1016/j.ejcsup.2013.07.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
394 Gallois A, Bhardwaj N. Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment. Front Immunol 2013;4:436. [PMID: 24339825 DOI: 10.3389/fimmu.2013.00436] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
395 Yang B, Chen J, Teng Y. TNPO1-Mediated Nuclear Import of FUBP1 Contributes to Tumor Immune Evasion by Increasing NRP1 Expression in Cervical Cancer. J Immunol Res 2021;2021:9994004. [PMID: 33987449 DOI: 10.1155/2021/9994004] [Reference Citation Analysis]
396 Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O'Connor KC. B cells in the pathophysiology of myasthenia gravis. Muscle Nerve 2018;57:172-84. [PMID: 28940642 DOI: 10.1002/mus.25973] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
397 Yazici O, Sendur MAN, Ozdemir N, Aksoy S. Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol 2016; 22(2): 471-489 [PMID: 26811601 DOI: 10.3748/wjg.v22.i2.471] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
398 Nagano M, Kohsaka S, Hayashi T, Ueno T, Kojima S, Shinozaki-Ushiku A, Morita S, Tsuda M, Tanaka S, Shinohara T, Omori Y, Sugaya F, Kato H, Narita Y, Nakajima J, Suzuki K, Takamochi K, Mano H. Comprehensive molecular profiling of pulmonary pleomorphic carcinoma. NPJ Precis Oncol 2021;5:57. [PMID: 34158601 DOI: 10.1038/s41698-021-00201-3] [Reference Citation Analysis]
399 Goldman N, Lomakova YD, Londregan J, Bucknum A, DePierri K, Somerville J, Riggs JE. High macrophage PD-L1 expression not responsible for T cell suppression. Cell Immunol 2018;324:50-8. [PMID: 29305065 DOI: 10.1016/j.cellimm.2017.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
400 Rech AJ, Vonderheide RH. Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment. Cancer Discov 2013;3:1330-2. [PMID: 24327693 DOI: 10.1158/2159-8290.CD-13-0775] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
401 Messeha SS, Zarmouh NO, Soliman KFA. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. Nutrients 2021;13:1718. [PMID: 34069461 DOI: 10.3390/nu13051718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
402 Regzedmaa O, Li Y, Li Y, Zhang H, Wang J, Gong H, Yuan Y, Li W, Liu H, Chen J. Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer. Onco Targets Ther 2019;12:10043-55. [PMID: 31819500 DOI: 10.2147/OTT.S216362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
403 Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, Yang Y, Huang Y, Zhao H, Zhang L. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016;6:20090. [PMID: 26822379 DOI: 10.1038/srep20090] [Cited by in Crossref: 95] [Cited by in F6Publishing: 106] [Article Influence: 15.8] [Reference Citation Analysis]
404 Stroopinsky D, Liegel J, Bhasin M, Cheloni G, Thomas B, Bhasin S, Panchal R, Ghiasuddin H, Rahimian M, Nahas M, Orr S, Capelletti M, Torres D, Tacettin C, Weinstock M, Bisharat L, Morin A, Mahoney KM, Ebert B, Stone R, Kufe D, Freeman GJ, Rosenblatt J, Avigan D. Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica 2021;106:1330-42. [PMID: 33538148 DOI: 10.3324/haematol.2020.259457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
405 Judge JM, Tillou JD, Slingluff CL Jr, Kern JA, Kron IL, Weiss GR. Surgical management of the patient with metastatic melanoma to the heart. J Card Surg 2013;28:124-8. [PMID: 23406162 DOI: 10.1111/jocs.12054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
406 Shao Z, Wang AZ, George DJ, Zhang T. Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. Asian J Urol 2016;3:268-77. [PMID: 29264195 DOI: 10.1016/j.ajur.2016.08.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
407 Rajan A, Schrump DS. Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. Semin Thorac Cardiovasc Surg 2015;27:36-48. [PMID: 26074108 DOI: 10.1053/j.semtcvs.2015.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
408 Salik B, Smyth MJ, Nakamura K. Targeting immune checkpoints in hematological malignancies. J Hematol Oncol 2020;13:111. [PMID: 32787882 DOI: 10.1186/s13045-020-00947-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
409 He HX, Gao Y, Fu JC, Zhou QH, Wang XX, Bai B, Li PF, Huang C, Rong QX, Ping LQ, He YX, Mao JY, Chen X, Huang HQ. VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma. Oncoimmunology 2021;10:1907059. [PMID: 33889438 DOI: 10.1080/2162402X.2021.1907059] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
410 Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One. 2015;10:e0130142. [PMID: 26086854 DOI: 10.1371/journal.pone.0130142] [Cited by in Crossref: 294] [Cited by in F6Publishing: 283] [Article Influence: 42.0] [Reference Citation Analysis]
411 Wang Y, Kong D, Wang C, Chen J, Li J, Liu Z, Li X, Wang Z, Yao G, Wang X. A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials. Technol Cancer Res Treat 2020;19:1533033820967454. [PMID: 33084525 DOI: 10.1177/1533033820967454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
412 Overgaard NH, Principe DR, Schachtschneider KM, Jakobsen JT, Rund LA, Grippo PJ, Schook LB, Jungersen G. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β+ T Cells and Differentiated γδ T Cells Alongside a Regulatory Response Mediated by FOXP3+ T Cells and Immunoregulatory Molecules. Front Immunol 2018;9:1301. [PMID: 29930558 DOI: 10.3389/fimmu.2018.01301] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
413 Yang X, Lei P, Huang L, Tang X, Wei B, Wei H. Prognostic value of LRRC4C in Colon and Gastric Cancers correlates with Tumour Microenvironment Immunity. Int J Biol Sci 2021;17:1413-27. [PMID: 33867855 DOI: 10.7150/ijbs.58876] [Reference Citation Analysis]
414 Liechtenstein T, Perez-Janices N, Blanco-Luquin I, Goyvaerts C, Schwarze J, Dufait I, Lanna A, Ridder M, Guerrero-Setas D, Breckpot K, Escors D. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology 2014;3:e945378. [PMID: 25954597 DOI: 10.4161/21624011.2014.945378] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
415 Shimizu K, Kotera Y, Aruga A, Takeshita N, Katagiri S, Ariizumi S, Takahashi Y, Yoshitoshi K, Takasaki K, Yamamoto M. Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. Hum Vaccin Immunother. 2014;10:970-976. [PMID: 24419174 DOI: 10.4161/hv.27678] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
416 Ernst MPT, Broeders M, Herrero-Hernandez P, Oussoren E, van der Ploeg AT, Pijnappel WWMP. Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease. Mol Ther Methods Clin Dev 2020;18:532-57. [PMID: 32775490 DOI: 10.1016/j.omtm.2020.06.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
417 Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology 2013;2:e26615. [PMID: 24251082 DOI: 10.4161/onci.26615] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 8.4] [Reference Citation Analysis]
418 Andersen MH. Anti-regulatory T cells. Semin Immunopathol 2017;39:317-26. [PMID: 27677755 DOI: 10.1007/s00281-016-0593-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
419 Sun F, Zhu Q, Li T, Saeed M, Xu Z, Zhong F, Song R, Huai M, Zheng M, Xie C, Xu L, Yu H. Regulating Glucose Metabolism with Prodrug Nanoparticles for Promoting Photoimmunotherapy of Pancreatic Cancer. Adv Sci (Weinh) 2021;8:2002746. [PMID: 33643795 DOI: 10.1002/advs.202002746] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
420 Hira-Miyazawa M, Nakamura H, Hirai M, Kobayashi Y, Kitahara H, Bou-Gharios G, Kawashiri S. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. Int J Oncol 2018;52:379-88. [PMID: 29345283 DOI: 10.3892/ijo.2017.4221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
421 Liu Q, Hu P, Deng G, Zhang J, Liang N, Xie J, Qiao L, Luo H, Zhang J. Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapy. Onco Targets Ther 2017;10:2147-54. [PMID: 28442923 DOI: 10.2147/OTT.S128451] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
422 Leinwand J, Miller G. Regulation and modulation of antitumor immunity in pancreatic cancer. Nat Immunol 2020;21:1152-9. [PMID: 32807942 DOI: 10.1038/s41590-020-0761-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
423 Zheng L. PD-L1 Expression in Pancreatic Cancer. J Natl Cancer Inst. 2017;109. [PMID: 28131993 DOI: 10.1093/jnci/djw304] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
424 Xu B, Jungbluth AA, Frosina D, Alzumaili B, Aleynick N, Slodkowska E, Higgins K, Ho A, Morris L, Ghossein R, Katabi N. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. Histopathology 2019;75:672-82. [PMID: 31237963 DOI: 10.1111/his.13944] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
425 Schiffmann I, Greve G, Jung M, Lübbert M. Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Epigenetics 2016;11:858-70. [PMID: 27846368 DOI: 10.1080/15592294.2016.1237345] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
426 Fan P, Zhao J, Meng Z, Wu H, Wang B, Wu H, Jin X. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. J Exp Clin Cancer Res 2019;38:47. [PMID: 30709380 DOI: 10.1186/s13046-019-1044-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
427 Lee SM, Wages NA, Goodman KA, Lockhart AC. Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician. JCO Precis Oncol 2021;5:317-24. [PMID: 34151131 DOI: 10.1200/PO.20.00379] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
428 Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res 2014;2:15-8. [PMID: 24778161 DOI: 10.1158/2326-6066.CIR-13-0146] [Cited by in Crossref: 73] [Cited by in F6Publishing: 25] [Article Influence: 8.1] [Reference Citation Analysis]
429 Ramos RI, Shaw MA, Foshag L, Stern SL, Rahimzadeh N, Elashoff D, Hoon DSB. Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients. Cancers (Basel) 2020;13:E91. [PMID: 33396862 DOI: 10.3390/cancers13010091] [Reference Citation Analysis]
430 Mehta A, Oklu R, Sheth RA. Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response? Gastroenterol Res Pract. 2016;2016:9251375. [PMID: 27051417 DOI: 10.1155/2016/9251375] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
431 Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol 2016;34:3733-9. [PMID: 27354476 DOI: 10.1200/JCO.2016.67.3467] [Cited by in Crossref: 415] [Cited by in F6Publishing: 227] [Article Influence: 83.0] [Reference Citation Analysis]
432 Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, Tamragouri K, Rhee K, Mohindra N, Villaflor V, Park W, Lopes G, Giles FJ. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Oncologist 2019;24:820-8. [PMID: 30867242 DOI: 10.1634/theoncologist.2018-0433] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
433 Miao J, Lu X, Hu Y, Piao C, Wu X, Liu X, Huang C, Wang Y, Li D, Liu J. Prostaglandin E2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment. Oncotarget 2017;8:89802-10. [PMID: 29163789 DOI: 10.18632/oncotarget.21155] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
434 Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 2015;6:26483-93. [PMID: 26317899 DOI: 10.18632/oncotarget.4494] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 14.7] [Reference Citation Analysis]
435 Zhang L, Yu JS. Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines. J Neurooncol 2019;143:429-36. [PMID: 31152305 DOI: 10.1007/s11060-019-03193-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
436 Jovanović D, Roksandić-Milenković M, Kotur-Stevuljević J, Ćeriman V, Vukanić I, Samardžić N, Popević S, Ilić B, Gajić M, Simon M, Simon I, Spasojević-Kalimanovska V, Belić M, Mirkov D, Šumarac Z, Milenković V. Soluble sPD-L1 and Serum Amyloid A1 as Potential Biomarkers for Lung Cancer. J Med Biochem 2019;38:332-41. [PMID: 31156344 DOI: 10.2478/jomb-2018-0036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
437 Glitza IC, Davies MA. Genotyping of cutaneous melanoma. Chin Clin Oncol 2014;3:27. [PMID: 25632386 DOI: 10.3978/j.issn.2304-3865.2014.03.01] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
438 Janakiram M, Pareek V, Cheng H, Narasimhulu DM, Zang X. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. Immunotherapy 2016;8:809-19. [PMID: 27349980 DOI: 10.2217/imt-2016-0001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
439 Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ; Ovarian Tumor Tissue Analysis (OTTA) Consortium. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol 2017;3:e173290. [PMID: 29049607 DOI: 10.1001/jamaoncol.2017.3290] [Cited by in Crossref: 113] [Cited by in F6Publishing: 120] [Article Influence: 37.7] [Reference Citation Analysis]
440 Wang Y, Liang Y, Xu H, Zhang X, Mao T, Cui J, Yao J, Wang Y, Jiao F, Xiao X, Hu J, Xia Q, Zhang X, Wang X, Sun Y, Fu D, Shen L, Xu X, Xue J, Wang L. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Cell Discov 2021;7:36. [PMID: 34035226 DOI: 10.1038/s41421-021-00271-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
441 Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 2015;38:1-11. [PMID: 25415283 DOI: 10.1097/cji.0000000000000062] [Cited by in Crossref: 232] [Cited by in F6Publishing: 176] [Article Influence: 33.1] [Reference Citation Analysis]
442 Munir Ahmad S, Martinenaite E, Hansen M, Junker N, Borch TH, Met Ö, Donia M, Svane IM, Andersen MH. PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. Oncoimmunology 2016;5:e1202391. [PMID: 27622072 DOI: 10.1080/2162402X.2016.1202391] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
443 Halbrook CJ, Pasca di Magliano M, Lyssiotis CA. Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2018;315:G27-35. [PMID: 29543507 DOI: 10.1152/ajpgi.00416.2017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
444 Cheng S, Pei R, Li J, Li B, Tang L, Yin T, Liu S. Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives. Ann Transl Med 2021;9:1481. [PMID: 34734033 DOI: 10.21037/atm-21-4294] [Reference Citation Analysis]
445 Jing W, McAllister D, Vonderhaar EP, Palen K, Riese MJ, Gershan J, Johnson BD, Dwinell MB. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. J Immunother Cancer 2019;7:115. [PMID: 31036082 DOI: 10.1186/s40425-019-0573-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
446 Yoon SH. Immunotherapy for non-small cell lung cancer. Tuberc Respir Dis (Seoul) 2014;77:111-5. [PMID: 25309605 DOI: 10.4046/trd.2014.77.3.111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
447 Kuehl PJ, Yingling CM, Dubose D, Burke M, Revelli DA, Chen W, Dye WW, Belinsky SA, Tessema M. Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer. Drug Deliv 2021;28:767-75. [PMID: 33860729 DOI: 10.1080/10717544.2021.1912209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
448 Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273-290. [PMID: 26977780 DOI: 10.1038/nrclinonc.2016.25] [Cited by in Crossref: 544] [Cited by in F6Publishing: 503] [Article Influence: 90.7] [Reference Citation Analysis]
449 Kovacsovics-Bankowski M, Chisholm L, Vercellini J, Tucker CG, Montler R, Haley D, Newell P, Ma J, Tseng P, Wolf R, Vetto JT, Hammill C, Hansen P, Weinberg AD. Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities. J Immunother Cancer 2014;2:38. [PMID: 25436113 DOI: 10.1186/s40425-014-0038-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
450 Spain L, Younger E, Hatipoglu E, Larkin J. Pembrolizumab in the management of metastatic melanoma. Melanoma Manag 2015;2:315-25. [PMID: 30190860 DOI: 10.2217/mmt.15.33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
451 John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2013;2:e26286. [PMID: 24353912 DOI: 10.4161/onci.26286] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 8.6] [Reference Citation Analysis]
452 Group Young Researchers In Inflammatory Carcinogenesis, Wandmacher AM, Mehdorn AS, Sebens S. The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer. Cancers (Basel) 2021;13:4932. [PMID: 34638420 DOI: 10.3390/cancers13194932] [Reference Citation Analysis]
453 Yang J, He X, Lv Q, Jing J, Shi H. Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. Front Pharmacol 2019;10:726. [PMID: 31312140 DOI: 10.3389/fphar.2019.00726] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
454 Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:20212-20217. [PMID: 24277834 DOI: 10.1073/pnas.1320318110] [Cited by in Crossref: 849] [Cited by in F6Publishing: 841] [Article Influence: 94.3] [Reference Citation Analysis]
455 Meyers DE, Bryan PM, Banerji S, Morris DG. Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. Curr Oncol 2018;25:e324-34. [PMID: 30111979 DOI: 10.3747/co.25.3976] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
456 Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med 2014;7:357-65. [PMID: 25484597 DOI: 10.2147/PGPM.S53163] [Cited by in Crossref: 9] [Cited by in F6Publishing: 40] [Article Influence: 1.1] [Reference Citation Analysis]
457 Vici P, Mariani L, Pizzuti L, Sergi D, Di Lauro L, Vizza E, Tomao F, Tomao S, Cavallotti C, Paolini F, Venuti A. Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res 2014;33:29. [PMID: 24667138 DOI: 10.1186/1756-9966-33-29] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
458 Kudo M. Pembrolizumab for the Treatment of Hepatocellular Carcinoma. Liver Cancer 2019;8:143-54. [PMID: 31192152 DOI: 10.1159/000500143] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
459 Principe DR, DeCant B, Mascariñas E, Wayne EA, Diaz AM, Akagi N, Hwang R, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, Grippo PJ. TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. Cancer Res 2016;76:2525-39. [PMID: 26980767 DOI: 10.1158/0008-5472.CAN-15-1293] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 14.3] [Reference Citation Analysis]
460 Marra A, Scognamiglio G, Peluso I, Botti G, Fusciello C, Filippelli A, Ascierto PA, Pepe S, Sabbatino F. Immune Checkpoint Inhibitors in Melanoma and HIV Infection. Open AIDS J 2017;11:91-100. [PMID: 29290886 DOI: 10.2174/1874613601711010091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
461 Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med (Maywood) 2015;240:1087-98. [PMID: 25956686 DOI: 10.1177/1535370215584936] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
462 Zamarin D, Jazaeri AA. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol 2016;141:86-94. [PMID: 27016233 DOI: 10.1016/j.ygyno.2015.12.030] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
463 Wang X, Feng M, Xiao T, Guo B, Liu D, Liu C, Pei J, Liu Q, Xiao Y, Rosin-Arbesfeld R, Shi Y, Zhou Y, Yang M, Feng YX, Jiang Y, Shao Z, Yu K, Zhu D. BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer. Oncogene 2021;40:2982-97. [PMID: 33767438 DOI: 10.1038/s41388-021-01756-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
464 Wu AA, Jaffee E, Lee V. Current Status of Immunotherapies for Treating Pancreatic Cancer. Curr Oncol Rep 2019;21:60. [PMID: 31101991 DOI: 10.1007/s11912-019-0811-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
465 Mony JT, Zhang L, Ma T, Grabosch S, Tirodkar TS, Brozick J, Tseng G, Elishaev E, Edwards RP, Huang X, Vlad AM. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. Cancer Immunol Immunother 2015;64:1095-108. [PMID: 25998800 DOI: 10.1007/s00262-015-1712-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
466 Fujiwara N, Watanabe M, Katayama A, Noda Y, Eguchi J, Kataoka H, Kagawa S, Wada J. Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases. Clin Case Rep 2021;9:e04574. [PMID: 34522382 DOI: 10.1002/ccr3.4574] [Reference Citation Analysis]
467 Hendry SA, Farnsworth RH, Solomon B, Achen MG, Stacker SA, Fox SB. The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. Front Immunol 2016;7:621. [PMID: 28066431 DOI: 10.3389/fimmu.2016.00621] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 12.5] [Reference Citation Analysis]
468 Cui J, Yang H, Liu J, Chen D, Hu J, Zhang H, Wang Y, Han T, Mao T, Jiao F, Biskup E, Pan Y, Liu M, Wang L. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer 2021;21:672. [PMID: 34098895 DOI: 10.1186/s12885-021-08375-6] [Reference Citation Analysis]
469 Zhou X, Liu X, Huang L. Macrophage-Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention. Adv Funct Mater 2021;31:2006220. [PMID: 33692665 DOI: 10.1002/adfm.202006220] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
470 Kashima Y, Togashi Y, Fukuoka S, Kamada T, Irie T, Suzuki A, Nakamura Y, Shitara K, Minamide T, Yoshida T, Taoka N, Kawase T, Wada T, Inaki K, Chihara M, Ebisuno Y, Tsukamoto S, Fujii R, Ohashi A, Suzuki Y, Tsuchihara K, Nishikawa H, Doi T. Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. Sci Rep 2021;11:341. [PMID: 33431933 DOI: 10.1038/s41598-020-79385-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
471 Wauters E, Vansteenkiste J. Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients? J Thorac Dis 2014;6:574-7. [PMID: 24976973 DOI: 10.3978/j.issn.2072-1439.2014.05.16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
472 Lu C, Liu K. Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy. Transl Cancer Res 2017;6:S652-4. [PMID: 30613482 DOI: 10.21037/tcr.2017.05.32] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
473 Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners B, Ferguson AK, Wilt C, Ko AH, Wang-Gillam A, Laheru DA, Anders RA, Thompson ED, Sugar EA, Jaffee EM, Le DT. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clin Cancer Res. 2020;26:5129-5139. [PMID: 32591464 DOI: 10.1158/1078-0432.ccr-20-1025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
474 Javadrashid D, Baghbanzadeh A, Derakhshani A, Leone P, Silvestris N, Racanelli V, Solimando AG, Baradaran B. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines 2021;9:373. [PMID: 33918146 DOI: 10.3390/biomedicines9040373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
475 Şahin S, Batur Ş, Aydın Ö, Öztürk T, Turna A, Öz B. Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis. Balkan Med J 2019;36:184-9. [PMID: 30592196 DOI: 10.4274/balkanmedj.galenos.2018.2018.0392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
476 Gbolahan O, O'Neil B. Update on systemic therapy for colorectal cancer: biologics take sides. Transl Gastroenterol Hepatol 2019;4:9. [PMID: 30976712 DOI: 10.21037/tgh.2019.01.12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
477 Yan Y, Gao R, Trinh TLP, Grant MB. Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics. Clin Cancer Res 2017;23:6363-73. [PMID: 28684632 DOI: 10.1158/1078-0432.CCR-17-0250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
478 Shen T, Chen Z, Zhao ZJ, Wu J. Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer. Oncotarget 2017;8:60975-86. [PMID: 28977839 DOI: 10.18632/oncotarget.17689] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
479 Stump CT, Roehle K, Manjarrez Orduno N, Dougan SK. Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer. Open Biol 2021;11:210245. [PMID: 34784792 DOI: 10.1098/rsob.210245] [Reference Citation Analysis]
480 Arroyo Hornero R, Georgiadis C, Hua P, Trzupek D, He LZ, Qasim W, Todd JA, Ferreira RC, Wood KJ, Issa F, Hester J. CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells. Commun Biol 2020;3:375. [PMID: 32665635 DOI: 10.1038/s42003-020-1097-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
481 Alambeladi S, Hosseiny S, Jafarinia M, Dianatpour M. Use of dual-transfection for programmed death cell protein 1 disruption mediated by CRISPR-Cas9 in human peripheral blood mononuclear cells. Iran J Basic Med Sci 2021;24:44-50. [PMID: 33643569 DOI: 10.22038/ijbms.2020.48566.11146] [Reference Citation Analysis]
482 Young MH, Pietz G, Whalen E, Copeland W, Thompson E, Fox BA, Newhall KJ. Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. Sci Rep 2021;11:16460. [PMID: 34385543 DOI: 10.1038/s41598-021-95902-x] [Reference Citation Analysis]
483 Bonavida B, Chouaib S. Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. Ann Oncol 2017;28:457-67. [PMID: 27864216 DOI: 10.1093/annonc/mdw615] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
484 Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CJ, Beiting DP, Girondo MA, Peck AR, Puré E, Chatterji P, Rustgi AK, Diehl JA, Koumenis C, Rui H, Fuchs SY. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell 2017;31:194-207. [PMID: 28196594 DOI: 10.1016/j.ccell.2017.01.004] [Cited by in Crossref: 106] [Cited by in F6Publishing: 103] [Article Influence: 21.2] [Reference Citation Analysis]
485 Yang WC, Lin SF. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. Biomed Res Int 2015;2015:341430. [PMID: 26649299 DOI: 10.1155/2015/341430] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
486 Chuang J, Chao J, Hendifar A, Klempner SJ, Gong J. Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. Transl Gastroenterol Hepatol 2019;4:63. [PMID: 31559344 DOI: 10.21037/tgh.2019.08.04] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
487 Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA, Guha U, Wang Y, Szabo E, Meltzer P, Steinberg SM, Trepel JB, Loehrer PJ, Giaccone G. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16:177-186. [PMID: 25592632 DOI: 10.1016/s1470-2045(14)71181-7] [Cited by in Crossref: 123] [Cited by in F6Publishing: 65] [Article Influence: 17.6] [Reference Citation Analysis]
488 Xue S, Hu M, Li P, Ma J, Xie L, Teng F, Zhu Y, Fan B, Mu D, Yu J. Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. Oncotarget 2017;8:49702-12. [PMID: 28591697 DOI: 10.18632/oncotarget.17922] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
489 Sakellariou-Thompson D, Forget MA, Hinchcliff E, Celestino J, Hwu P, Jazaeri AA, Haymaker C, Bernatchez C. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. Cancer Immunol Immunother 2019;68:1747-57. [PMID: 31602489 DOI: 10.1007/s00262-019-02402-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
490 Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 2015;12:511-26. [PMID: 25963091 DOI: 10.1038/nrclinonc.2015.90] [Cited by in Crossref: 155] [Cited by in F6Publishing: 157] [Article Influence: 22.1] [Reference Citation Analysis]
491 Chiarucci C, Cannito S, Daffinà MG, Amato G, Giacobini G, Cutaia O, Lofiego MF, Fazio C, Giannarelli D, Danielli R, Di Giacomo AM, Coral S, Calabrò L, Maio M, Covre A. Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. Cancers (Basel) 2020;12:E361. [PMID: 32033266 DOI: 10.3390/cancers12020361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
492 Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014;2:616-631. [PMID: 24942756 DOI: 10.1158/2326-6066.cir-14-0027] [Cited by in Crossref: 264] [Cited by in F6Publishing: 166] [Article Influence: 33.0] [Reference Citation Analysis]
493 Steele NG, Carpenter ES, Kemp SB, Sirihorachai V, The S, Delrosario L, Lazarus J, Amir ED, Gunchick V, Espinoza C, Bell S, Harris L, Lima F, Irizarry-Negron V, Paglia D, Macchia J, Chu AKY, Schofield H, Wamsteker EJ, Kwon R, Schulman A, Prabhu A, Law R, Sondhi A, Yu J, Patel A, Donahue K, Nathan H, Cho C, Anderson MA, Sahai V, Lyssiotis CA, Zou W, Allen BL, Rao A, Crawford HC, Bednar F, Frankel TL, Pasca di Magliano M. Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. Nat Cancer 2020;1:1097-112. [PMID: 34296197 DOI: 10.1038/s43018-020-00121-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 13.5] [Reference Citation Analysis]
494 Heinrich B, Goepfert K, Delic M, Galle PR, Moehler M. Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. Onco Targets Ther 2013;6:1119-27. [PMID: 23986643 DOI: 10.2147/OTT.S49371] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
495 Nelson BS, Lin L, Kremer DM, Sousa CM, Cotta-Ramusino C, Myers A, Ramos J, Gao T, Kovalenko I, Wilder-Romans K, Dresser J, Davis M, Lee HJ, Nwosu ZC, Campit S, Mashadova O, Nicolay BN, Tolstyka ZP, Halbrook CJ, Chandrasekaran S, Asara JM, Crawford HC, Cantley LC, Kimmelman AC, Wahl DR, Lyssiotis CA. Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy. Cancer Metab 2020;8:1. [PMID: 31908776 DOI: 10.1186/s40170-019-0202-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
496 Abolhassani AR, Schuler G, Kirchberger MC, Heinzerling L. C-reactive protein as an early marker of immune-related adverse events. J Cancer Res Clin Oncol 2019;145:2625-31. [PMID: 31492984 DOI: 10.1007/s00432-019-03002-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
497 Liang M, Schwickart M, Schneider AK, Vainshtein I, Del Nagro C, Standifer N, Roskos LK. Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. Cytometry B Clin Cytom 2016;90:117-27. [PMID: 26054054 DOI: 10.1002/cyto.b.21259] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
498 Hwang S, Kwon AY, Jeong JY, Kim S, Kang H, Park J, Kim JH, Han OJ, Lim SM, An HJ. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci Rep 2020;10:643. [PMID: 31959763 DOI: 10.1038/s41598-019-57218-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 18.5] [Reference Citation Analysis]
499 Freire J, Ajona D, de Biurrun G, Agorreta J, Segura V, Guruceaga E, Bleau AM, Pio R, Blanco D, Montuenga LM. Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment. Neoplasia 2013;15:913-24. [PMID: 23908592 DOI: 10.1593/neo.13310] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
500 Ferreira MP, Coghill AE, Chaves CB, Bergmann A, Thuler LC, Soares EA, Pfeiffer RM, Engels EA, Soares MA. Outcomes of cervical cancer among HIV-infected and HIV-uninfected women treated at the Brazilian National Institute of Cancer. AIDS 2017;31:523-31. [PMID: 28060014 DOI: 10.1097/QAD.0000000000001367] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
501 Dillman RO. Is vaccine research still relevant for metastatic melanoma? Melanoma Manag 2014;1:91-4. [PMID: 30190814 DOI: 10.2217/mmt.14.18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
502 Ozimski LL, Gremmelspacher D, Aceto N. A fatal affair: Circulating tumor cell relationships that shape metastasis. iScience 2021;24:103073. [PMID: 34568794 DOI: 10.1016/j.isci.2021.103073] [Reference Citation Analysis]
503 Schaue D. A Century of Radiation Therapy and Adaptive Immunity. Front Immunol. 2017;8:431. [PMID: 28443099 DOI: 10.3389/fimmu.2017.00431] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
504 Cooper AJ, Carlino MS, Kefford RF. Immune checkpoint inhibitors in melanoma. Melanoma Manag 2015;2:267-84. [PMID: 30190854 DOI: 10.2217/mmt.15.17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
505 Day NB, Wixson WC, Shields CW 4th. Magnetic systems for cancer immunotherapy. Acta Pharm Sin B 2021;11:2172-96. [PMID: 34522583 DOI: 10.1016/j.apsb.2021.03.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
506 Hayes DN, Kim WY. The next steps in next-gen sequencing of cancer genomes. J Clin Invest 2015;125:462-8. [PMID: 25642706 DOI: 10.1172/JCI68339] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
507 Ijsselsteijn ME, Brouwer TP, Abdulrahman Z, Reidy E, Ramalheiro A, Heeren AM, Vahrmeijer A, Jordanova ES, de Miranda NF. Cancer immunophenotyping by seven-colour multispectral imaging without tyramide signal amplification. J Pathol Clin Res 2019;5:3-11. [PMID: 30191683 DOI: 10.1002/cjp2.113] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
508 Ishikawa E, Kato S, Shimada K, Tanaka T, Suzuki Y, Satou A, Kohno K, Sakakibara A, Yamamura T, Nakamura M, Miyahara R, Goto H, Nakamura S, Hirooka Y. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells. Cancer Med 2018;7:6051-63. [PMID: 30449068 DOI: 10.1002/cam4.1875] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
509 Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S. Peptide-based PET quantifies target engagement of PD-L1 therapeutics. J Clin Invest 2019;129:616-30. [PMID: 30457978 DOI: 10.1172/JCI122216] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 12.7] [Reference Citation Analysis]
510 Itoh S, Yugawa K, Shimokawa M, Yoshiya S, Mano Y, Takeishi K, Toshima T, Maehara Y, Mori M, Yoshizumi T. Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection. BJS Open 2019;3:500-8. [PMID: 31388642 DOI: 10.1002/bjs5.50170] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
511 Arensman MD, Yang XS, Leahy DM, Toral-Barza L, Mileski M, Rosfjord EC, Wang F, Deng S, Myers JS, Abraham RT, Eng CH. Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity. Proc Natl Acad Sci U S A 2019;116:9533-42. [PMID: 31019077 DOI: 10.1073/pnas.1814932116] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 17.3] [Reference Citation Analysis]
512 Li H, Xu J, Bai Y, Zhang S, Cheng M, Jin J. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. Invest New Drugs 2021;39:860-70. [PMID: 33409896 DOI: 10.1007/s10637-020-01039-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
513 Wang J, Xie L, Miao Y, Liu X, Tang Y, Xi Y, Chang J, Wu Y, Jiang L. Adult pulmonary Langerhans cell histiocytosis might consist of two distinct groups: isolated form and extrapulmonary recidivism type. Ann Transl Med 2021;9:357. [PMID: 33708984 DOI: 10.21037/atm-20-8141] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
514 Charoentong P, Angelova M, Efremova M, Gallasch R, Hackl H, Galon J, Trajanoski Z. Bioinformatics for cancer immunology and immunotherapy. Cancer Immunol Immunother 2012;61:1885-903. [PMID: 22986455 DOI: 10.1007/s00262-012-1354-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
515 Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 2014;11:237-46. [PMID: 25610709 DOI: 10.7497/j.issn.2095-3941.2014.04.002] [Cited by in F6Publishing: 36] [Reference Citation Analysis]
516 Wang L, Wang FS. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Hepatol Int 2019;13:521-33. [PMID: 31352593 DOI: 10.1007/s12072-019-09967-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
517 Feng E, Zheng T, He X, Chen J, Tian Y. A novel ternary heterostructure with dramatic SERS activity for evaluation of PD-L1 expression at the single-cell level. Sci Adv 2018;4:eaau3494. [PMID: 30406203 DOI: 10.1126/sciadv.aau3494] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
518 Weiss JM, Stinchcombe TE. Second-Line Therapy for Advanced NSCLC. Oncologist 2013;18:947-53. [PMID: 23918070 DOI: 10.1634/theoncologist.2013-0096] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
519 Khodadoust MS, Alizadeh AA. Tumor antigen discovery through translation of the cancer genome. Immunol Res 2014;58:292-9. [PMID: 24718952 DOI: 10.1007/s12026-014-8505-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
520 Hutchinson KE, Johnson DB, Johnson AS, Sanchez V, Kuba M, Lu P, Chen X, Kelley MC, Wang Q, Zhao Z, Kris M, Berger MF, Sosman JA, Pao W. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget 2015;6:22348-60. [PMID: 26084293 DOI: 10.18632/oncotarget.4255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
521 Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015;36:587-95. [PMID: 26162965 DOI: 10.1016/j.tips.2015.06.005] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 14.4] [Reference Citation Analysis]
522 Nowicki TS, Anderson JL, Federman N. Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. Pediatr Res 2016;79:371-7. [PMID: 26595537 DOI: 10.1038/pr.2015.246] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
523 Huang X, Tang T, Zhang G, Hong Z, Xu J, Yadav DK, Bai X, Liang T. Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. NPJ Precis Oncol 2020;4:29. [PMID: 33299118 DOI: 10.1038/s41698-020-00136-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
524 Du Z, Abedalthagafi M, Aizer AA, McHenry AR, Sun HH, Bray MA, Viramontes O, Machaidze R, Brastianos PK, Reardon DA, Dunn IF, Freeman GJ, Ligon KL, Carpenter AE, Alexander BM, Agar NY, Rodig SJ, Bradshaw EM, Santagata S. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 2015;6:4704-16. [PMID: 25609200 DOI: 10.18632/oncotarget.3082] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 13.5] [Reference Citation Analysis]
525 Sukari A, Nagasaka M, Alhasan R, Patel D, Wozniak A, Ramchandren R, Vaishampayan U, Weise A, Flaherty L, Jang H, Kim S, Gadgeel S. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. Anticancer Res 2019;39:781-90. [PMID: 30711957 DOI: 10.21873/anticanres.13175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
526 Batur S, Dulger O, Durak S, Yumuk PF, Caglar HB, Bozkurtlar E, Bozkurt S, Tastekin E, Cicin I, Ahiskali R, Rzazade R, Cakir A, Oz B. Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases. Bosn J Basic Med Sci 2020;20:329-35. [PMID: 31999935 DOI: 10.17305/bjbms.2019.4474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
527 Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep 2017;7:5532. [PMID: 28717238 DOI: 10.1038/s41598-017-06002-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 14.6] [Reference Citation Analysis]
528 Tsukagoshi M, Wada S, Hirono S, Yoshida S, Yada E, Sasada T, Shirabe K, Kuwano H, Yamaue H. Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer. Oncotarget 2018;9:31448-58. [PMID: 30140382 DOI: 10.18632/oncotarget.25837] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
529 Kiyotani K, Chan HT, Nakamura Y. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci 2018;109:542-9. [PMID: 29288513 DOI: 10.1111/cas.13498] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
530 Shah DJ, Dronca RS. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc 2014;89:504-19. [PMID: 24684873 DOI: 10.1016/j.mayocp.2014.02.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 7.3] [Reference Citation Analysis]
531 Sankin A, Narasimhulu D, John P, Gartrell B, Schoenberg M, Zang X. The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1. Urol Oncol 2018;36:459-68. [PMID: 28495553 DOI: 10.1016/j.urolonc.2017.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
532 Rahn S, Krüger S, Mennrich R, Goebel L, Wesch D, Oberg HH, Vogel I, Ebsen M, Röcken C, Helm O, Sebens S. POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma. Oncotarget 2019;10:1572-88. [PMID: 30899426 DOI: 10.18632/oncotarget.26705] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
533 Parilla M, Ritterhouse LL. Beyond the Variants: Mutational Patterns in Next-Generation Sequencing Data for Cancer Precision Medicine. Front Cell Dev Biol 2020;8:370. [PMID: 32509788 DOI: 10.3389/fcell.2020.00370] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
534 Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550. [PMID: 28018338 DOI: 10.3389/fimmu.2016.00550] [Cited by in Crossref: 219] [Cited by in F6Publishing: 226] [Article Influence: 36.5] [Reference Citation Analysis]
535 Frebel H, Nindl V, Schuepbach RA, Braunschweiler T, Richter K, Vogel J, Wagner CA, Loffing-Cueni D, Kurrer M, Ludewig B, Oxenius A. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J Exp Med 2012;209:2485-99. [PMID: 23230000 DOI: 10.1084/jem.20121015] [Cited by in Crossref: 118] [Cited by in F6Publishing: 116] [Article Influence: 11.8] [Reference Citation Analysis]
536 Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
537 Suozzi KC, Stahl M, Ko CJ, Chiang A, Gettinger SN, Siegel MD, Bunick CG. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep 2016;2:264-8. [PMID: 27486590 DOI: 10.1016/j.jdcr.2016.05.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 10.8] [Reference Citation Analysis]
538 Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, Zhu L, Zhu J, Joshi M, Belani CP. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget 2016;7:56233-40. [PMID: 27191652 DOI: 10.18632/oncotarget.9316] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
539 Monabati A, Nematollahi P, Dehghanian A, Safaei A, Sadeghipour A, Movahedinia S, Mokhtari M. Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. Basic Clin Neurosci 2020;11:491-8. [PMID: 33613887 DOI: 10.32598/bcn.11.4.2542.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
540 Kobayashi Y, Watanabe T. Artificial Construction of Immune Tissues/Organoids and Their Application for Immunological Intervention. Curr Top Microbiol Immunol 2020;426:143-60. [PMID: 32483658 DOI: 10.1007/82_2020_215] [Reference Citation Analysis]
541 He R, Lao Y, Yu W, Zhang X, Jiang M, Zhu C. Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer. Front Oncol 2021;11:764618. [PMID: 34888243 DOI: 10.3389/fonc.2021.764618] [Reference Citation Analysis]
542 Singh PP, Sharma PK, Krishnan G, Lockhart AC. Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf). 2015;3:289-297. [PMID: 26510455 DOI: 10.1093/gastro/gov053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
543 Fazzari FGT, Rose F, Pauls M, Guay E, Ibrahim MFK, Basulaiman B, Tu M, Hutton B, Nicholas G, Ng TL. The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials. Crit Rev Oncol Hematol 2021;169:103540. [PMID: 34808376 DOI: 10.1016/j.critrevonc.2021.103540] [Reference Citation Analysis]
544 Shen L, Gao Y, Liu Y, Zhang B, Liu Q, Wu J, Fan L, Ou Q, Zhang W, Shao L. PD-1/PD-L pathway inhibits M.tb-specific CD4+ T-cell functions and phagocytosis of macrophages in active tuberculosis. Sci Rep 2016;6:38362. [PMID: 27924827 DOI: 10.1038/srep38362] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
545 Hamada T, Keum N, Nishihara R, Ogino S. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol. 2017;52:265-275. [PMID: 27738762 DOI: 10.1007/s00535-016-1272-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 10.8] [Reference Citation Analysis]
546 Xu G, Sun L, Li Y, Xie F, Zhou X, Yang H, Du S, Xu H, Mao Y. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Front Oncol 2019;9:897. [PMID: 31620360 DOI: 10.3389/fonc.2019.00897] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
547 Das S, Berlin J, Cardin D. Harnessing the Immune System in Pancreatic Cancer. Curr Treat Options Oncol 2018;19:48. [PMID: 30128712 DOI: 10.1007/s11864-018-0566-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
548 Wang HC, Hung WC, Chen LT, Pan MR. From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. Int J Mol Sci 2018;19:E3584. [PMID: 30428588 DOI: 10.3390/ijms19113584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
549 Gao CE, Zhang M, Song Q, Dong J. PD-1 inhibitors dependent CD8+ T cells inhibit mouse colon cancer cell metastasis. Onco Targets Ther 2019;12:6961-71. [PMID: 31695411 DOI: 10.2147/OTT.S202941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
550 Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA, Pilon-Thomas S. Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy. PLoS One 2016;11:e0153053. [PMID: 27050669 DOI: 10.1371/journal.pone.0153053] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
551 Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther 2012;12:1597-611. [PMID: 23253225 DOI: 10.1586/era.12.147] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 8.8] [Reference Citation Analysis]
552 Van Audenaerde JR, Marcq E, von Scheidt B, Davey AS, Oliver AJ, De Waele J, Quatannens D, Van Loenhout J, Pauwels P, Roeyen G, Lardon F, Slaney CY, Peeters M, Kershaw MH, Darcy PK, Smits EL. Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment. Clin Transl Immunology. 2020;9:e1165. [PMID: 32821382 DOI: 10.1002/cti2.1165] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
553 He J, Huo L, Ma J, Zhao J, Bassett RL, Sun X, Ueno NT, Lim B, Gong Y. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 2018;149:253-61. [PMID: 29425258 DOI: 10.1093/ajcp/aqx162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
554 Kapke J, Shaheen Z, Kilari D, Knudson P, Wong S. Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. Case Rep Oncol 2017;10:897-909. [PMID: 29279690 DOI: 10.1159/000480634] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
555 Pham TND, Shields MA, Spaulding C, Principe DR, Li B, Underwood PW, Trevino JG, Bentrem DJ, Munshi HG. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers (Basel) 2021;13:440. [PMID: 33503832 DOI: 10.3390/cancers13030440] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
556 Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M. Immunotherapeutic Advances for NSCLC. Biologics 2021;15:399-417. [PMID: 34675481 DOI: 10.2147/BTT.S295406] [Reference Citation Analysis]
557 Tang H, Zhu M, Qiao J, Fu YX. Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. Cell Mol Immunol 2017;14:809-18. [PMID: 28413217 DOI: 10.1038/cmi.2017.13] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
558 Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging 2017;44:2310-25. [PMID: 28815334 DOI: 10.1007/s00259-017-3802-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
559 Jarkowski A 3rd, Khushalani NI. BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog 2014;13:1. [PMID: 24737949 DOI: 10.4103/1477-3163.126759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
560 Pyo J, Park HJ. Treatment Efficacy of Immune Checkpoint Inhibitors for Patients with Advanced or Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:3599. [PMID: 34441895 DOI: 10.3390/jcm10163599] [Reference Citation Analysis]
561 Harshman LC, Drake CG, Choueiri TK. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2014;2:1132-41. [PMID: 25480555 DOI: 10.1158/2326-6066.CIR-14-0193] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 4.1] [Reference Citation Analysis]
562 Kim VM, Pan X, Soares KC, Azad NS, Ahuja N, Gamper CJ, Blair AB, Muth S, Ding D, Ladle BH, Zheng L. Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. JCI Insight 2020;5:136368. [PMID: 32376802 DOI: 10.1172/jci.insight.136368] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
563 Ibarrondo FJ, Yang OO, Chodon T, Avramis E, Lee Y, Sazegar H, Jalil J, Chmielowski B, Koya RC, Schmid I, Gomez-Navarro J, Jamieson BD, Ribas A, Comin-Anduix B. Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One 2013;8:e76829. [PMID: 24167550 DOI: 10.1371/journal.pone.0076829] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
564 Almagro JC, Gilliland GL, Breden F, Scott JK, Sok D, Pauthner M, Reichert JM, Helguera G, Andrabi R, Mabry R, Bléry M, Voss JE, Laurén J, Abuqayyas L, Barghorn S, Ben-Jacob E, Crowe JE Jr, Huston JS, Johnston SA, Krauland E, Lund-Johansen F, Marasco WA, Parren PW, Xu KY. Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. MAbs 2014;6:577-618. [PMID: 24589717 DOI: 10.4161/mabs.28421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
565 Rekhtman N, Ang DC, Riely GJ, Ladanyi M, Moreira AL. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol 2013;26:1307-19. [PMID: 23619604 DOI: 10.1038/modpathol.2013.74] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 7.7] [Reference Citation Analysis]
566 Gammelgaard OL, Terp MG, Preiss B, Ditzel HJ. Human cancer evolution in the context of a human immune system in mice. Mol Oncol 2018;12:1797-810. [PMID: 30120895 DOI: 10.1002/1878-0261.12374] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
567 Iovanna J. Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. Transl Oncol 2021;14:100965. [PMID: 33248412 DOI: 10.1016/j.tranon.2020.100965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
568 Adams DL, Alpaugh RK, Tsai S, Tang CM, Stefansson S. Multi-Phenotypic subtyping of circulating tumor cells using sequential fluorescent quenching and restaining. Sci Rep 2016;6:33488. [PMID: 27647345 DOI: 10.1038/srep33488] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
569 Binder DC, Davis AA, Wainwright DA. Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology 2016;5:e1082027. [PMID: 27057463 DOI: 10.1080/2162402X.2015.1082027] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 7.9] [Reference Citation Analysis]
570 Brouwer TP, Vahrmeijer AL, de Miranda NFCC. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cell Oncol (Dordr) 2021;44:261-78. [PMID: 33710604 DOI: 10.1007/s13402-021-00587-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
571 Nielsen MFB, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol 2016; 22(9): 2678-2700 [PMID: 26973408 DOI: 10.3748/wjg.v22.i9.2678] [Cited by in CrossRef: 127] [Cited by in F6Publishing: 112] [Article Influence: 21.2] [Reference Citation Analysis]
572 Przystal JM, Becker H, Canjuga D, Tsiami F, Anderle N, Keller AL, Pohl A, Ries CH, Schmittnaegel M, Korinetska N, Koch M, Schittenhelm J, Tatagiba M, Schmees C, Beck SC, Tabatabai G. Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. Cancers (Basel) 2021;13:2400. [PMID: 34063518 DOI: 10.3390/cancers13102400] [Reference Citation Analysis]
573 Mori S, Kurimoto T, Ueda K, Enomoto H, Sakamoto M, Keshi Y, Yamada Y, Nakamura M. Optic Neuritis Possibly Induced by Anti-PD-L1 Antibody Treatment in a Patient with Non-Small Cell Lung Carcinoma. Case Rep Ophthalmol 2018;9:348-56. [PMID: 30140221 DOI: 10.1159/000491075] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
574 McGuigan AJ, Coleman HG, McCain RS, Kelly PJ, Johnston DI, Taylor MA, Turkington RC. Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. J Pathol Clin Res 2021;7:99-112. [PMID: 33481339 DOI: 10.1002/cjp2.192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
575 Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Moretta F, Mingari MC, Salgarello M, Terzi A, Picece V, Pomari C, Lunardi G, Cavazza A, Rossi G, Moretta L, Bogina G. PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. Oncotarget 2017;8:90123-31. [PMID: 29163815 DOI: 10.18632/oncotarget.21485] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 11.2] [Reference Citation Analysis]
576 Mayer AT, Natarajan A, Gordon SR, Maute RL, McCracken MN, Ring AM, Weissman IL, Gambhir SS. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. J Nucl Med 2017;58:538-46. [PMID: 27980047 DOI: 10.2967/jnumed.116.177659] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 12.8] [Reference Citation Analysis]
577 Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265-276. [PMID: 25797516 DOI: 10.1016/j.it.2015.02.008] [Cited by in Crossref: 517] [Cited by in F6Publishing: 493] [Article Influence: 73.9] [Reference Citation Analysis]
578 Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, Wakimoto H, Fisher D, Shah K. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci U S A 2017;114:E6157-65. [PMID: 28710334 DOI: 10.1073/pnas.1700363114] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 9.2] [Reference Citation Analysis]
579 Pauken KE, Godec J, Odorizzi PM, Brown KE, Yates KB, Ngiow SF, Burke KP, Maleri S, Grande SM, Francisco LM, Ali MA, Imam S, Freeman GJ, Haining WN, Wherry EJ, Sharpe AH. The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection. Cell Rep 2020;31:107827. [PMID: 32610128 DOI: 10.1016/j.celrep.2020.107827] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
580 Hazama S, Tamada K, Yamaguchi Y, Kawakami Y, Nagano H. Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Ann Gastroenterol Surg. 2018;2:289-303. [PMID: 30003192 DOI: 10.1002/ags3.12180] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
581 Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? World J Gastroenterol 2018; 24(20): 2137-2151 [PMID: 29853732 DOI: 10.3748/wjg.v24.i20.2137] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 54] [Article Influence: 15.8] [Reference Citation Analysis]
582 Zhu J, Zhang T, Li J, Lin J, Liang W, Huang W, Wan N, Jiang J. Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis. Front Pharmacol 2019;10:673. [PMID: 31258479 DOI: 10.3389/fphar.2019.00673] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
583 MacFarlane AW 4th, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2014;2:320-31. [PMID: 24764579 DOI: 10.1158/2326-6066.CIR-13-0133] [Cited by in Crossref: 92] [Cited by in F6Publishing: 72] [Article Influence: 10.2] [Reference Citation Analysis]
584 Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.Viruses. 2015;7:6009-6042. [PMID: 26610547 DOI: 10.3390/v7112923] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
585 Coventry BJ, Baume D, Lilly C. Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds? Cancer Manag Res 2015;7:93-103. [PMID: 25995649 DOI: 10.2147/CMAR.S76163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
586 Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A 2019;116:1692-7. [PMID: 30635425 DOI: 10.1073/pnas.1811067116] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 34.7] [Reference Citation Analysis]
587 Podgrabinska S, Skobe M. Role of lymphatic vasculature in regional and distant metastases. Microvasc Res 2014;95:46-52. [PMID: 25026412 DOI: 10.1016/j.mvr.2014.07.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 6.9] [Reference Citation Analysis]
588 Kim HM, Lee J, Koo JS. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. BMC Cancer 2017;17:690. [PMID: 29041905 DOI: 10.1186/s12885-017-3670-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
589 Zhao J, Bao W, Cai W. Immune Infiltration Landscape in Lung Squamous Cell Carcinoma Implications. Biomed Res Int 2020;2020:5981870. [PMID: 33102584 DOI: 10.1155/2020/5981870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
590 Nagaya T, Nakamura Y, Sato K, Harada T, Choyke PL, Hodge JW, Schlom J, Kobayashi H. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget. 2017;8:8807-8817. [PMID: 27716622 DOI: 10.18632/oncotarget.12410] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
591 Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 2020;11:603. [PMID: 32001676 DOI: 10.1038/s41467-019-14273-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 23.5] [Reference Citation Analysis]
592 Balsitis S, Gali V, Mason PJ, Chaniewski S, Levine SM, Wichroski MJ, Feulner M, Song Y, Granaldi K, Loy JK, Thompson CM, Lesniak JA, Brockus C, Kishnani N, Menne S, Cockett MI, Iyer R, Mason SW, Tenney DJ. Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. PLoS One 2018;13:e0190058. [PMID: 29444087 DOI: 10.1371/journal.pone.0190058] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
593 Zhang H, Jiang R, Zhou J, Wang J, Xu Y, Zhang H, Gu Y, Fu F, Shen Y, Zhang G, Feng L, Zhang X, Chen Y, Shen F. CTL Attenuation Regulated by PS1 in Cancer-Associated Fibroblast. Front Immunol 2020;11:999. [PMID: 32587587 DOI: 10.3389/fimmu.2020.00999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
594 Zinselmeyer BH, Heydari S, Sacristán C, Nayak D, Cammer M, Herz J, Cheng X, Davis SJ, Dustin ML, McGavern DB. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med 2013;210:757-74. [PMID: 23530125 DOI: 10.1084/jem.20121416] [Cited by in Crossref: 155] [Cited by in F6Publishing: 151] [Article Influence: 17.2] [Reference Citation Analysis]
595 Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K, Ohta H, Kim S, Okagawa T, Izumi Y, Deguchi T, Kato Y, Yamamoto S, Yamamoto K, Toda M, Nakajima C, Suzuki Y, Murata S, Ohashi K. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol 2021;5:10. [PMID: 33580183 DOI: 10.1038/s41698-021-00147-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
596 Hu X, Wang J, Chu M, Liu Y, Wang ZW, Zhu X. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy. Mol Ther 2021;29:908-19. [PMID: 33388422 DOI: 10.1016/j.ymthe.2020.12.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
597 Lu P, Youngblood BA, Austin JW, Mohammed AU, Butler R, Ahmed R, Boss JM. Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. J Exp Med 2014;211:515-27. [PMID: 24590765 DOI: 10.1084/jem.20130208] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 11.1] [Reference Citation Analysis]
598 Seifert AM, Eymer A, Heiduk M, Wehner R, Tunger A, von Renesse J, Decker R, Aust DE, Welsch T, Reissfelder C, Weitz J, Schmitz M, Seifert L. PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer. Cancers (Basel) 2020;12:E2756. [PMID: 32987956 DOI: 10.3390/cancers12102756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
599 Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, Chang KM, Sulkowski M, Marro SO, Anderson J, He B, Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selby M, Korman AJ, Lowy I. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 2013;8:e63818. [PMID: 23717490 DOI: 10.1371/journal.pone.0063818] [Cited by in Crossref: 173] [Cited by in F6Publishing: 167] [Article Influence: 19.2] [Reference Citation Analysis]
600 Langhammer S, Scheerer J. Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget 2017;8:43555-70. [PMID: 28402937 DOI: 10.18632/oncotarget.16674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
601 Sobral-Leite M, Van de Vijver K, Michaut M, van der Linden R, Hooijer GKJ, Horlings HM, Severson TM, Mulligan AM, Weerasooriya N, Sanders J, Glas AM, Wehkamp D, Mittempergher L, Kersten K, Cimino-Mathews A, Peters D, Hooijberg E, Broeks A, van de Vijver MJ, Bernards R, Andrulis IL, Kok M, de Visser KE, Schmidt MK. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. Oncoimmunology 2018;7:e1509820. [PMID: 30524905 DOI: 10.1080/2162402X.2018.1509820] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
602 Kim ES, Kim JE, Patel MA, Mangraviti A, Ruzevick J, Lim M. Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. J Immunol Res 2016;2016:4683607. [PMID: 26881264 DOI: 10.1155/2016/4683607] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
603 Bezu L, Sauvat A, Humeau J, Gomes-da-Silva LC, Iribarren K, Forveille S, Garcia P, Zhao L, Liu P, Zitvogel L, Senovilla L, Kepp O, Kroemer G. eIF2α phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ 2018;25:1375-93. [PMID: 29358668 DOI: 10.1038/s41418-017-0044-9] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 19.5] [Reference Citation Analysis]
604 Wasiuk A, Testa J, Weidlick J, Sisson C, Vitale L, Widger J, Crocker A, Thomas LJ, Goldstein J, Marsh HC, Keler T, He LZ. CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy. J Immunol 2017;199:4110-23. [PMID: 29109120 DOI: 10.4049/jimmunol.1700606] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
605 Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013;19:1035-43. [PMID: 23460534 DOI: 10.1158/1078-0432.CCR-12-2064] [Cited by in Crossref: 265] [Cited by in F6Publishing: 187] [Article Influence: 29.4] [Reference Citation Analysis]
606 Lu P, Liang W, Li J, Hong Y, Chen Z, Liu T, Dong P, Huang H, Zhang T, Jiang J. A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma. Front Pharmacol 2020;11:619. [PMID: 32457618 DOI: 10.3389/fphar.2020.00619] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
607 Möhn N, Beutel G, Gutzmer R, Ivanyi P, Satzger I, Skripuletz T. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook. J Clin Med 2019;8:E1777. [PMID: 31653079 DOI: 10.3390/jcm8111777] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
608 Vincent MD. Promising targets and current clinical trials in metastatic squamous cell lung cancer. Front Oncol 2014;4:320. [PMID: 25538887 DOI: 10.3389/fonc.2014.00320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
609 Song Z, Yu X, Cheng G, Zhang Y. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. J Transl Med 2016;14:188. [PMID: 27342566 DOI: 10.1186/s12967-016-0943-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 50] [Article Influence: 6.7] [Reference Citation Analysis]
610 Janakiram M, Chinai JM, Fineberg S, Fiser A, Montagna C, Medavarapu R, Castano E, Jeon H, Ohaegbulam KC, Zhao R, Zhao A, Almo SC, Sparano JA, Zang X. Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. Clin Cancer Res 2015;21:2359-66. [PMID: 25549724 DOI: 10.1158/1078-0432.CCR-14-1495] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 8.4] [Reference Citation Analysis]
611 Femia D, Prinzi N, Anichini A, Mortarini R, Nichetti F, Corti F, Torchio M, Peverelli G, Pagani F, Maurichi A, Mattavelli I, Milione M, Bedini N, Corti A, Di Bartolomeo M, de Braud F, Pusceddu S. Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. Target Oncol 2018;13:567-82. [PMID: 30073632 DOI: 10.1007/s11523-018-0585-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
612 王维嘉, 王丹, 秦国慧, 陈新峰, 张毅. 免疫检查点抑制剂在结直肠癌中的应用以及未来发展方向. 世界华人消化杂志 2017; 25(19): 1714-1727 [DOI: 10.11569/wcjd.v25.i19.1714] [Reference Citation Analysis]
613 Sun NY, Chen YL, Wu WY, Lin HW, Chiang YC, Chang CF, Tai YJ, Hsu HC, Chen CA, Sun WZ, Cheng WF. Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization. Cancers (Basel) 2019;11:E1400. [PMID: 31546897 DOI: 10.3390/cancers11091400] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
614 Harshman LC, Choueiri TK, Drake C, Stephen Hodi F Jr. Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J 2014;20:272-80. [PMID: 25098288 DOI: 10.1097/PPO.0000000000000055] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
615 Tang R, Liu X, Wang W, Hua J, Xu J, Liang C, Meng Q, Liu J, Zhang B, Yu X, Shi S. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Cancer Cell Int 2021;21:196. [PMID: 33827590 DOI: 10.1186/s12935-021-01900-4] [Reference Citation Analysis]
616 Zhao R, Xiao Q, Li M, Ren W, Xia C, Liu X, Li Y, Tan T, Wu D, Sun L. Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy. Antib Ther 2020;3:63-70. [PMID: 32391516 DOI: 10.1093/abt/tbaa004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
617 Fang Z, Jiang C, Li S. The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy. Front Immunol 2020;11:617583. [PMID: 33613544 DOI: 10.3389/fimmu.2020.617583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
618 Cao Q, Wang W, Zhou M, Huang Q, Wen X, Zhao J, Shi S, Geng K, Li F, Hatakeyama H, Xu C, Piwnica-Worms D, Peng W, Zhou D, Sood AK, Li C. Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition. Nanomedicine 2020;25:102169. [PMID: 32059873 DOI: 10.1016/j.nano.2020.102169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
619 Shan F, Sun L, Zhang L, Guo K, Yan Q, Feng G, Zhu Y, Shen M, Ruan S. Inhibition to Epithelial-Mesenchymal Transition and Metastatic Potential In Colorectal Cancer Cell By Combination of Traditional Chinese Medicine Formulation Jiedu Sangen Decoction and PD-L1 Inhibitor. Integr Cancer Ther 2020;19:1534735420972486. [PMID: 33238770 DOI: 10.1177/1534735420972486] [Reference Citation Analysis]
620 Adamopoulos C, Gargalionis AN, Basdra EK, Papavassiliou AG. Deciphering signaling networks in osteosarcoma pathobiology. Exp Biol Med (Maywood) 2016;241:1296-305. [PMID: 27190271 DOI: 10.1177/1535370216648806] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
621 De Felice F, Marchetti C, Palaia I, Musio D, Muzii L, Tombolini V, Panici PB. Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. J Immunol Res 2015;2015:191832. [PMID: 26236750 DOI: 10.1155/2015/191832] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
622 Zhang G, Li N, Li Z, Zhu Q, Li F, Yang C, Han Q, Lv Y, Zhou Z, Liu Z. microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases. Oncotarget. 2015;6:18933-18944. [PMID: 25895129 DOI: 10.18632/oncotarget.3662] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
623 Ganesan A, Ahmed M, Okoye I, Arutyunova E, Babu D, Turnbull WL, Kundu JK, Shields J, Agopsowicz KC, Xu L, Tabana Y, Srivastava N, Zhang G, Moon TC, Belovodskiy A, Hena M, Kandadai AS, Hosseini SN, Hitt M, Walker J, Smylie M, West FG, Siraki AG, Lemieux MJ, Elahi S, Nieman JA, Tyrrell DL, Houghton M, Barakat K. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. Sci Rep 2019;9:12392. [PMID: 31455818 DOI: 10.1038/s41598-019-48826-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
624 Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199-4206. [PMID: 24127452 DOI: 10.1200/jco.2012.48.3685] [Cited by in Crossref: 335] [Cited by in F6Publishing: 175] [Article Influence: 37.2] [Reference Citation Analysis]
625 He Y, Rivard CJ, Rozeboom L, Yu H, Ellison K, Kowalewski A, Zhou C, Hirsch FR. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci. 2016;107:1193-1197. [PMID: 27297395 DOI: 10.1111/cas.12986] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 14.2] [Reference Citation Analysis]
626 White RR, Murphy JD, Martin RCG. The Landmark Series: Locally Advanced Pancreatic Cancer and Ablative Therapy Options. Ann Surg Oncol 2021;28:4173-80. [PMID: 33586072 DOI: 10.1245/s10434-021-09662-z] [Reference Citation Analysis]
627 Pasquier J, Ghiabi P, Chouchane L, Razzouk K, Rafii S, Rafii A. Angiocrine endothelium: from physiology to cancer. J Transl Med 2020;18:52. [PMID: 32014047 DOI: 10.1186/s12967-020-02244-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
628 Zou R, Wang Y, Ye F, Zhang X, Wang M, Cui S. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. Clin Transl Oncol 2021. [PMID: 34002348 DOI: 10.1007/s12094-021-02637-2] [Reference Citation Analysis]
629 Seshacharyulu P, Baine MJ, Souchek JJ, Menning M, Kaur S, Yan Y, Ouellette MM, Jain M, Lin C, Batra SK. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2017;1868:69-92. [PMID: 28249796 DOI: 10.1016/j.bbcan.2017.02.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
630 Pillarisetty VG. The pancreatic cancer microenvironment: an immunologic battleground. Oncoimmunology. 2014;3:e950171. [PMID: 25610740 DOI: 10.4161/21624011.2014.950171] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
631 Lennon S, Oweida A, Milner D, Phan AV, Bhatia S, Van Court B, Darragh L, Mueller AC, Raben D, Martínez-Torrecuadrada JL, Pitts TM, Somerset H, Jordan KR, Hansen KC, Williams J, Messersmith WA, Schulick RD, Owens P, Goodman KA, Karam SD. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. Clin Cancer Res 2019;25:3352-65. [PMID: 30944125 DOI: 10.1158/1078-0432.CCR-18-2811] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
632 Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 2015;16:e534-42. [PMID: 26545842 DOI: 10.1016/S1470-2045(15)00088-1] [Cited by in Crossref: 359] [Cited by in F6Publishing: 194] [Article Influence: 59.8] [Reference Citation Analysis]
633 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509-2520. [PMID: 26028255 DOI: 10.1056/nejmoa1500596] [Cited by in Crossref: 4650] [Cited by in F6Publishing: 2768] [Article Influence: 664.3] [Reference Citation Analysis]
634 de Ruiter JR, Wessels LFA, Jonkers J. Mouse models in the era of large human tumour sequencing studies. Open Biol 2018;8:180080. [PMID: 30111589 DOI: 10.1098/rsob.180080] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
635 Watanabe R, Shirai T, Namkoong H, Zhang H, Berry GJ, Wallis BB, Schaefgen B, Harrison DG, Tremmel JA, Giacomini JC, Goronzy JJ, Weyand CM. Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. J Clin Invest 2017;127:2725-38. [PMID: 28604383 DOI: 10.1172/JCI92167] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
636 Choi JR, Kim MJ, Tae N, Wi TM, Kim SH, Lee ES, Kim DH. BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody. Viruses 2020;12:E684. [PMID: 32630442 DOI: 10.3390/v12060684] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
637 Kim H, Kwon HJ, Park SY, Park Y, Park E, Chung JH. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer. PLoS One 2018;13:e0198634. [PMID: 29856861 DOI: 10.1371/journal.pone.0198634] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
638 Park R, Winnicki M, Liu E, Chu WM. Immune checkpoints and cancer in the immunogenomics era. Brief Funct Genomics 2019;18:133-9. [PMID: 30137232 DOI: 10.1093/bfgp/ely027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
639 Suarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, Zhu Q, Marasco WA. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget 2016;7:34341-55. [PMID: 27145284 DOI: 10.18632/oncotarget.9114] [Cited by in Crossref: 143] [Cited by in F6Publishing: 141] [Article Influence: 35.8] [Reference Citation Analysis]
640 Andersen MH. Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. J Natl Cancer Inst 2015;107:djv154. [PMID: 26063792 DOI: 10.1093/jnci/djv154] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
641 Verdon DJ, Jenkins MR. Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy. Cancers (Basel) 2021;13:4245. [PMID: 34439399 DOI: 10.3390/cancers13164245] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
642 Liu J, Blake SJ, Smyth MJ, Teng MW. Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunology 2014;3:e22. [PMID: 25505970 DOI: 10.1038/cti.2014.18] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
643 Krog RT, de Miranda NFCC, Vahrmeijer AL, Kooreman NG. The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:5789. [PMID: 34830945 DOI: 10.3390/cancers13225789] [Reference Citation Analysis]
644 Khan E, Shrestha AK, Elkhooly M, Wilson H, Ebbert M, Srivastava S, Wen S, Rollins S, Sriwastava S. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review. J Neurol Sci 2022;432:120089. [PMID: 34942546 DOI: 10.1016/j.jns.2021.120089] [Reference Citation Analysis]
645 Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman HB, Larman T, Taverna G, Cosottini M, Lupi I. Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. Am J Pathol 2016;186:3225-35. [PMID: 27750046 DOI: 10.1016/j.ajpath.2016.08.020] [Cited by in Crossref: 158] [Cited by in F6Publishing: 138] [Article Influence: 26.3] [Reference Citation Analysis]
646 Coward JI, Middleton K, Murphy F. New perspectives on targeted therapy in ovarian cancer. Int J Womens Health 2015;7:189-203. [PMID: 25678824 DOI: 10.2147/IJWH.S52379] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
647 Terrén I, Orrantia A, Mikelez-Alonso I, Vitallé J, Zenarruzabeitia O, Borrego F. NK Cell-Based Immunotherapy in Renal Cell Carcinoma. Cancers (Basel) 2020;12:E316. [PMID: 32013092 DOI: 10.3390/cancers12020316] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
648 Duffy AG, Makarova-Rusher OV, Greten TF. The case for immune-based approaches in biliary tract carcinoma. Hepatology 2016;64:1785-91. [PMID: 27177447 DOI: 10.1002/hep.28635] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
649 Vanella V, Festino L, Strudel M, Simeone E, Grimaldi AM, Ascierto PA. PD-L1 inhibitors in the pipeline: Promise and progress. Oncoimmunology 2017;7:e1365209. [PMID: 29296516 DOI: 10.1080/2162402X.2017.1365209] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
650 Tsutsumi S, Saeki H, Nakashima Y, Ito S, Oki E, Morita M, Oda Y, Okano S, Maehara Y. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. Cancer Sci 2017;108:1119-27. [PMID: 28294486 DOI: 10.1111/cas.13237] [Cited by in Crossref: 58] [Cited by in F6Publishing: 66] [Article Influence: 11.6] [Reference Citation Analysis]
651 Park SJ, Kim H, Shin K, Lee MA, Hong TH. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol 2019; 11(11): 1021-1030 [PMID: 31798782 DOI: 10.4251/wjgo.v11.i11.1021] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
652 Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo T, Sato T, Kudo M, Ito A, Nakagawa K. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017;35:529-536. [PMID: 28317087 DOI: 10.1007/s10637-017-0453-0] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 13.4] [Reference Citation Analysis]
653 Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 2018;18:91-104. [PMID: 28990586 DOI: 10.1038/nri.2017.112] [Cited by in Crossref: 187] [Cited by in F6Publishing: 183] [Article Influence: 37.4] [Reference Citation Analysis]
654 Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen H, Cuevas C, Dotson AM, Tan X, Hotes JL, Greenberg PD. T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2015;28:638-652. [PMID: 26525103 DOI: 10.1016/j.ccell.2015.09.022] [Cited by in Crossref: 109] [Cited by in F6Publishing: 106] [Article Influence: 15.6] [Reference Citation Analysis]
655 Apolo AB. PDL1: The Illusion of an Ideal Biomarker. Eur Urol Focus 2016;1:269-71. [PMID: 28723398 DOI: 10.1016/j.euf.2015.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
656 Frick M, Mouchacca P, Verdeil G, Hamon Y, Billaudeau C, Buferne M, Fallet M, Auphan-Anezin N, Schmitt-Verhulst AM, Boyer C. Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca2+ signalling and granule mobilization. Immunology 2017;150:199-212. [PMID: 27716898 DOI: 10.1111/imm.12679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
657 Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, Nik-Zainal S, Steenbruggen TG, Tjan-Heijnen VCG, Labots M, van Riel JMGH, Bloemendal HJ, Steeghs N, Lolkema MP, Voest EE, van de Werken HJG, Jager A, Cuppen E, Sleijfer S, Martens JWM. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet 2019;51:1450-8. [PMID: 31570896 DOI: 10.1038/s41588-019-0507-7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 75] [Article Influence: 30.0] [Reference Citation Analysis]
658 Ferrara R, Pilotto S, Caccese M, Grizzi G, Sperduti I, Giannarelli D, Milella M, Besse B, Tortora G, Bria E. Do immune checkpoint inhibitors need new studies methodology? J Thorac Dis 2018;10:S1564-80. [PMID: 29951307 DOI: 10.21037/jtd.2018.01.131] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
659 O'Neill RE, Cao X. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. Adv Cancer Res 2019;143:145-94. [PMID: 31202358 DOI: 10.1016/bs.acr.2019.03.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
660 Navas-Delgado I, García-Nieto J, López-Camacho E, Rybinski M, Lavado R, Berciano Guerrero MÁ, Aldana-Montes JF. VIGLA-M: visual gene expression data analytics. BMC Bioinformatics 2019;20:150. [PMID: 30999846 DOI: 10.1186/s12859-019-2695-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
661 Hue JJ, Bingmer K, Sugumar K, Markt SC, Rothermel LD, Hardacre JM, Ammori JB, Winter JM, Ocuin LM. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. J Pancreat Cancer 2021;7:31-8. [PMID: 33937617 DOI: 10.1089/pancan.2021.0003] [Reference Citation Analysis]
662 Itatani Y, Yamamoto T, Zhong C, Molinolo AA, Ruppel J, Hegde P, Taketo MM, Ferrara N. Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proc Natl Acad Sci U S A 2020;117:21598-608. [PMID: 32817421 DOI: 10.1073/pnas.2008112117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
663 Young K, Hughes DJ, Cunningham D, Starling N. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. Ther Adv Med Oncol. 2018;10:1758835918816281. [PMID: 30574212 DOI: 10.1177/1758835918816281] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
664 Dhar M, Wong J, Che J, Matsumoto M, Grogan T, Elashoff D, Garon EB, Goldman JW, Sollier Christen E, Di Carlo D, Kulkarni RP. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Sci Rep 2018;8:2592. [PMID: 29416054 DOI: 10.1038/s41598-018-19245-w] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 10.8] [Reference Citation Analysis]
665 Ongaro T, Gouyou B, Stringhini M, Corbellari R, Neri D, Villa A. A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo. Oncotarget 2020;11:3698-711. [PMID: 33110477 DOI: 10.18632/oncotarget.27726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
666 Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM, Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, Eron JJ; AIDS Clinical Trials 5326 Study Team. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. J Infect Dis 2017;215:1725-33. [PMID: 28431010 DOI: 10.1093/infdis/jix191] [Cited by in Crossref: 128] [Cited by in F6Publishing: 124] [Article Influence: 25.6] [Reference Citation Analysis]
667 Guo C, Tang Y, Zhang Y, Li G. Mining TCGA Data for Key Biomarkers Related to Immune Microenvironment in Endometrial cancer by Immune Score and Weighted Correlation Network Analysis. Front Mol Biosci 2021;8:645388. [PMID: 33869285 DOI: 10.3389/fmolb.2021.645388] [Reference Citation Analysis]
668 Wu L, Xie S, Wang L, Li J, Han L, Qin B, Zhang G, Wu Q, Gao W, Zhang L, Wei H, Liu T, Jiao S. The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy. Front Immunol 2021;12:665147. [PMID: 33912192 DOI: 10.3389/fimmu.2021.665147] [Reference Citation Analysis]
669 Murthy P, Ekeke CN, Russell KL, Butler SC, Wang Y, Luketich JD, Soloff AC, Dhupar R, Lotze MT. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology 2019;8:e1554969. [PMID: 30906651 DOI: 10.1080/2162402X.2018.1554969] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
670 Zhang QF, Li J, Jiang K, Wang R, Ge JL, Yang H, Liu SJ, Jia LT, Wang L, Chen BL. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Theranostics 2020;10:10619-33. [PMID: 32929370 DOI: 10.7150/thno.44871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
671 Hossain MS, Kunter GM, El-Najjar VF, Jaye DL, Al-Kadhimi Z, Taofeek OK, Li JM, Waller EK. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients. PLoS One 2017;12:e0184254. [PMID: 28953925 DOI: 10.1371/journal.pone.0184254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
672 Brady J, Horie S, Laffey JG. Role of the adaptive immune response in sepsis. Intensive Care Med Exp 2020;8:20. [PMID: 33336293 DOI: 10.1186/s40635-020-00309-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
673 Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 2014;14:748. [PMID: 25288198 DOI: 10.1186/1471-2407-14-748] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 8.1] [Reference Citation Analysis]
674 Whitehurst M, Chiappori A. Immunotherapy treatments for small-cell lung cancer: past, present and future. Lung Cancer Manag 2013;2:517-25. [PMID: 26236401 DOI: 10.2217/lmt.13.62] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
675 Caruana I, Simula L, Locatelli F, Campello S. T lymphocytes against solid malignancies: winning ways to defeat tumours. Cell Stress 2018;2:200-12. [PMID: 31225487 DOI: 10.15698/cst2018.07.148] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
676 Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer 2016;4:3. [PMID: 26788324 DOI: 10.1186/s40425-016-0107-3] [Cited by in Crossref: 126] [Cited by in F6Publishing: 115] [Article Influence: 21.0] [